{"id":440460,"date":"2026-05-31T03:25:00","date_gmt":"2026-05-30T19:25:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=440460"},"modified":"2026-05-31T03:25:00","modified_gmt":"2026-05-30T19:25:00","slug":"menarini-group-%e6%96%bc-2026-%e5%b9%b4%e7%be%8e%e5%9c%8b%e8%87%a8%e5%ba%8a%e8%85%ab%e7%98%a4%e5%ad%b8%e6%9c%83-asco-%e9%80%b1%e5%b9%b4%e5%a4%a7%e6%9c%83%e4%b8%8a%e7%99%bc%e8%a1%a8%e7%ac%ac-1b-2","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=440460","title":{"rendered":"Menarini Group \u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u767c\u8868\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u4f7f\u7528\u57c3\u62c9\u53f8\u7fa4 (Elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (Capivasertib) \u6cbb\u7642 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u6700\u65b0\u6578\u64da\u3002"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><i>ELEVATE \u7814\u7a76\u4e2d\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7b2c 1b \u671f\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u5206\u6790\u7d50\u679c\u4ee4\u4eba\u9f13\u821e\uff0c\u76f8\u95dc\u8cc7\u6599\u5c07\u516c\u958b\u767c\u8868\u3002<\/i><\/li>\n<li><i>\u7642\u6548\u6578\u64da\u7a81\u986f\u4e86\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u6709\u671b\u89e3\u6c7a ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u95dc\u9375\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u7576\u4e2d\u5305\u62ec <\/i>ESR1<i> \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002<\/i><\/li>\n<li><i>\u516c\u53f8\u4ea6\u5c07\u5206\u4eab\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u8a72\u85e5\u7269\u5728\u8f49\u79fb\u6027\u4e73\u764c\u806f\u5408\u6cbb\u7642\u60c5\u5883\u4e2d\uff0c\u4ee5\u53ca\u65e9\u671f\u4e73\u764c\u55ae\u85e5\u6cbb\u7642\u4e2d\u7684\u61c9\u7528\u6f5b\u529b\u3002<\/i><\/li>\n<\/ul>\n<p><b>\u50c5\u4f9b<\/b><b>\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u5a92\u9ad4\u4f7f\u7528<\/b><\/p>\n<p><span class=\"legendSpanClass\">\u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d04<\/span><span class=\"legendSpanClass\">2026\u5e745\u670831\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; \u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u8207\u8a3a\u65b7\u516c\u53f8 The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff0c\u7c21\u7a31\u300cMenarini\u300d\uff09\u53ca\u5176\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u7c21\u7a31\u300cStemline\u300d\uff09\u5c07\u767c\u8868\u5176\u7b2c 1b\/2 \u671f <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05563220\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">ELEVATE<\/a> \u7814\u7a76\u4e2d\uff0c\u63a1\u7528\u57c3\u62c9\u53f8\u7fa4 (elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib) \u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4\u9670\u6027 (HER2-) \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c \u60a3\u8005\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\u3002Stemline \u5c08\u6ce8\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 \u6b64\u5916\uff0c\u4ea6\u6703\u767c\u8868\u5176\u4ed6\u591a\u9805\u6b63\u5728\u9032\u884c\u4e2d\u8a66\u9a57\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u57c3\u62c9\u53f8\u7fa4\u65bc\u4e73\u764c\u5404\u75c5\u7a0b\u968e\u6bb5\u4e2d\uff0c\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642 (endocrine therapy, ET) \u9aa8\u5e79\u85e5\u7269\u7684\u6f5b\u529b\u3002 \u6b64\u7b49\u6578\u64da\u5c07\u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u3002<\/p>\n<p>ELEVATE \u7814\u7a76\u76ee\u7684\u5728\u65bc\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u671f\u671b\u514b\u670d ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u4e26\u4e14\u5728\u4e0d\u8ad6 <i>ESR1<\/i> \u7a81\u8b8a\u72c0\u614b\u5982\u4f55\u7684\u60c5\u6cc1\u4e0b\uff0c\u63d0\u5347\u60a3\u8005\u6cbb\u7642\u6210\u679c\u3002 \u7814\u7a76\u5305\u542b\u516d\u7a2e\u6cbb\u7642\u65b9\u6848\uff0c\u5206\u5225\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207 CDK4\/6 \u6291\u5236\u5291\uff08\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u53ca\u745e\u535a\u897f\u5229 (ribociclib)\uff09\uff0c\u4ee5\u53ca PI3K\/AKT\/mTOR \u8a0a\u865f\u50b3\u5c0e\u9014\u5f91\u6291\u5236\u5291\uff08\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u963f\u57f9\u5229\u897f (alpelisib) \u548c\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\uff09\u806f\u5408\u6cbb\u7642\u7684\u7642\u6548\u3002<\/p>\n<p>2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u7684 ELEVATE \u7814\u7a76\u7d50\u679c\uff08\u6458\u8981 1098\uff09<sup>[1]<\/sup> \u4e2d\uff0c\u5305\u62ec\u4f86\u81ea\u57c3\u62c9\u53f8\u7fa4 (258-345 \u6beb\u514b) \u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c (320-400 \u6beb\u514b) \u7b2c 1b \u671f\u968a\u5217 (n=31) \u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\uff0c\u9019\u4e9b\u6578\u64da\u986f\u793a\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf (RP2D) \u968a\u5217\u4e2d\uff0c\u60a3\u8005\u5c55\u73fe\u51fa\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7372\u76ca\u3002 \u5728\u7b2c 2 \u968a\u5217 (n=9) \u4e2d\u78ba\u7acb\u7684\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u70ba\u57c3\u62c9\u53f8\u7fa4 345 \u6beb\u514b\uff0c\u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c 320 \u6beb\u514b\uff0c\u6bcf\u65e5\u5169\u6b21\uff08\u63a1 4 \u5929\u7528\u85e5\uff0f3 \u5929\u505c\u85e5\u7684\u65b9\u5f0f\uff09\u3002<\/p>\n<p>\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u53ef\u8a55\u4f30\u53cd\u61c9\u7684\u60a3\u8005\u4e2d\uff0c\u521d\u6b65\u7642\u6548\u986f\u793a\u75be\u75c5\u63a7\u5236\u7387 (DCR) \u70ba 88.9%\uff0c24 \u9031\u81e8\u5e8a\u7372\u76ca\u7387 (CBR24) \u70ba 66.7%\uff0c\u800c\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR) \u5247\u70ba 33.3%\u3002 \u6240\u6709\u51fa\u73fe\u5ba2\u89c0\u7de9\u89e3\u7387\u7684\u60a3\u8005\u7686\u5177\u6709 <i>ESR1<\/i> \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002 \u4e2d\u4f4d\u53cd\u61c9\u6301\u7e8c\u6642\u9593 (mDOR) \u5c1a\u672a\u9054\u5230\u3002 \u00a0\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u7684\u6574\u9ad4\u8a66\u9a57\u4eba\u7fa4\u4e2d\uff0c\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u70ba 11.3 \u500b\u6708\uff0c\u800c\u5177\u6709 <i>ESR1<\/i> \u8207 PIK3CA \u5171\u5b58\u7a81\u8b8a\u7684\u60a3\u8005\u5247\u70ba 10.9 \u500b\u6708\u3002 \u6b64\u5916\uff0c\u9019\u4e9b\u521d\u6b65\u7d50\u679c\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8868\u73fe\u8207\u5404\u7d44\u6a19\u9776\u6cbb\u7642\u914d\u5408\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002<\/p>\n<p>Dana-Farber Cancer Institute\uff08\u4e39\u5a1c &#8211; \u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff09\u4e73\u817a\u816b\u7624\u79d1\u4e3b\u4efb\uff0c\u91ab\u5b78\u535a\u58eb\u3001\u516c\u5171\u885b\u751f\u78a9\u58eb Sara Tolaney \u8868\u793a\uff1a\u300c\u57c3\u62c9\u53f8\u7fa4\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u806f\u5408\u7642\u6cd5\uff0c\u65e8\u5728\u89e3\u6c7a ER+\/HER2-\u3001PI3K \u8def\u5f91\u767c\u751f\u6539\u8b8a\u7684\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u5c1a\u672a\u7372\u5f97\u6eff\u8db3\u7684\u6cbb\u7642\u9700\u6c42\uff0c\u7279\u5225\u662f\u5728 <i>ESR1<\/i> \u8207 PIK3CA \u7a81\u8b8a\u540c\u6642\u51fa\u73fe\u7684\u60c5\u6cc1\u4e0b\u3002\u00a0 \u9019\u4e9b\u4ee4\u4eba\u9f13\u821e\u7684\u521d\u6b65\u6578\u64da\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u5177\u6709\u5ef6\u9577\u81e8\u5e8a\u6548\u76ca\u7684\u6f5b\u529b\uff0c\u800c\u5176\u5b89\u5168\u6027\u4ea6\u5c6c\u53ef\u63a7\uff0c\u7686\u56e0\u5b83\u53ef\u4ee5\u540c\u6642\u91dd\u5c0d <i>ESR1<\/i> \u8207 PIK3CA \u7a81\u8b8a\uff0c\u5f9e\u800c\u6709\u53ef\u80fd\u907f\u514d\u5c0d\u6bcf\u500b\u9776\u9ede\u9010\u4e00\u63a1\u7528\u5e8f\u5217\u6cbb\u7642\u7684\u9700\u8981\u3002\u300d<\/p>\n<p>Menarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300c\u57fa\u65bc\u6211\u5011\u53bb\u5e74\u5728\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u770b\u5230\u7684\u6578\u64da\uff0c\u6211\u5011\u7e7c\u7e8c\u5c0d\u57c3\u62c9\u53f8\u7fa4\u5728\u8207\u4e0d\u540c\u4f5c\u7528\u6a5f\u5236\u85e5\u7269\u7d44\u6210\u7684\u591a\u7a2e\u806f\u5408\u7642\u6cd5\u4e2d\uff0c\u91dd\u5c0d ER+\/HER2\u2212 \u8f49\u79fb\u6027\u4e73\u764c\u6240\u5c55\u73fe\u51fa\u7684\u6f5b\u5728\u81e8\u5e8a\u6548\u76ca\u611f\u5230\u9f13\u821e\u3002 \u6211\u5011\u7684\u7814\u7a76\u7bc4\u570d\u5ee3\u6cdb\uff0c\u6db5\u84cb\u65e9\u671f\u4e73\u764c\uff0c\u4ee5\u53ca\u591a\u7a2e\u91dd\u5c0d ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u7684\u806f\u5408\u7642\u6cd5\uff08\u5305\u62ec\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u806f\u5408\u7642\u6cd5\uff09\uff0c\u5c55\u73fe\u51fa\u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u6f5b\u5728\u8b8a\u9769\u6027\u6cbb\u7642\u65b9\u6848\u7684\u627f\u8afe\u3002\u300d<\/p>\n<p>\u6b64\u5916\uff0c\u5176\u4ed6\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u7684\u6578\u64da\u4ea6\u5c07\u65bc\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u5927\u6703\u4e0a\u516c\u4f48\u3002 \u4ee5\u4e0b\u662f\u5373\u5c07\u8209\u884c\u7c21\u5831\u7684\u5b8c\u6574\u540d\u55ae\uff1a<\/p>\n<p><b>\u7c21\u5831\u6a19\u984c\uff1a<\/b>\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u6cbb\u7642 ER+\/HER2- \u665a\u671f\u4e73\u764c\u60a3\u8005\uff1aELEVATE \u7814\u7a76\uff08\u4e00\u9805\u7b2c 1b\/2 \u671f\u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\uff09\u7684\u6700\u65b0\u9032\u5c55<br \/><b>\u6458\u8981\u7de8\u865f\uff1a<\/b>1098<br \/><b>\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a<\/b>2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09<br \/><b>\u5730\u9ede\uff1a<\/b>\u7b2c 212 \u865f\u6d77\u5831\u677f<br \/><b>\u5831\u544a\u4f5c\u8005\uff1a<\/b> Wassim McHayleh<\/p>\n<p><b>\u7c21\u5831\u6a19\u984c\uff1a<\/b>ADELA\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u5206\u7d44\u7684\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\uff0c\u5c0d\u6bd4\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5b89\u6170\u5291\u5728\u60a3\u6709 ER+\/HER2- \u665a\u671f\u4e73\u764c\u4e14\u816b\u7624\u5e36\u6709 ESR1 \u7a81\u8b8a\uff0c\u4e26\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642\u9023\u540c CDK4\/6 \u6291\u5236\u5291*# \u5f8c\u75c5\u60c5\u60e1\u5316\u60a3\u8005\u4e2d\u7684\u7642\u6548<br \/><b>\u6458\u8981\u7de8\u865f\uff1a<\/b>TPS1154<br \/><b>\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a<\/b>2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09<br \/><b>\u5730\u9ede\uff1a<\/b>\u7b2c 262b \u865f\u6d77\u5831\u677f<br \/><b>\u5831\u544a\u4f5c\u8005\uff1a<\/b> Antonio Llombart-Cussac<\/p>\n<p><b>\u7c21\u5831\u6a19\u984c\uff1a<\/b>ELECTRA\uff1a\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u591a\u4e2d\u5fc3\u3001\u7b2c 1b\/2 \u671f\u7814\u7a76\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u5728\u60a3\u6709\u8166\u90e8\u8f49\u79fb\u7684 ER+\/HER2- \u4e73\u764c\u60a3\u8005\u4e2d\u7684\u7642\u6548<br \/><b>\u6458\u8981\u7de8\u865f\uff1a<\/b>TPS1155<br \/><b>\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a<\/b>2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09<br \/><b>\u5730\u9ede\uff1a<\/b>\u7b2c 263a \u865f\u6d77\u5831\u677f<br \/><b>\u5831\u544a\u4f5c\u8005\uff1a<\/b>Nuhad Ibrahim<\/p>\n<p><b>\u7c21\u5831\u6a19\u984c\uff1a<\/b>CAPELA\uff1a\u4e00\u9805\u7b2c 2 \u671f\u591a\u4e2d\u5fc3\u958b\u653e\u6a19\u7c64\u96a8\u6a5f\u7814\u7a76\uff0c\u8a55\u4f30\u5361\u57f9\u4ed6\u6ff1 (capecitabine) \u806f\u5408\u57c3\u62c9\u53f8\u7fa4\uff0c\u76f8\u8f03\u65bc\u55ae\u7368\u4f7f\u7528\u5361\u57f9\u4ed6\u6ff1\u6cbb\u7642\u665a\u671f\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u4e73\u764c (TBCRC 070)* \u7684\u7642\u6548<br \/><b>\u6458\u8981\u7de8\u865f\uff1a<\/b>TPS1156<br \/><b>\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a<\/b>2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09<br \/><b>\u5730\u9ede\uff1a<\/b>\u7b2c 263b \u865f\u6d77\u5831\u677f<br \/><b>\u5831\u544a\u4f5c\u8005\uff1a<\/b>Kristina Fanucci<\/p>\n<p><b>\u7c21\u5831\u6a19\u984c\uff1a<\/b>ELEGANT\uff1a\u5728\u4e00\u9805\u5168\u7403\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\u4e2d\uff0c\u6bd4\u8f03\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u7528\u65bc\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548 <br \/><b>\u6458\u8981\u7de8\u865f\uff1a<\/b>TPS1153<br \/><b>\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a<\/b>2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09<br \/><b>\u5730\u9ede\uff1a<\/b>\u7b2c 262a \u865f\u6d77\u5831\u677f<br \/><b>\u5831\u544a\u4f5c\u8005\uff1a<\/b>Aditya Bardia<\/p>\n<p><i>*<\/i><i>\u8868\u793a\u7814\u7a76\u8005\u767c\u8d77\u7814\u7a76\u6216\u5408\u4f5c\u7814\u7a76<\/i><\/p>\n<p><i>#ADELA \u7814\u7a76\u662f\u4e00\u9805\u8207 MEDSIR \u5171\u540c\u8d0a\u52a9\u7684\u95dc\u9375\u6027\u7814\u7a76<\/i><\/p>\n<p><b>\u95dc\u65bc\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283<\/b><\/p>\n<p>\u57c3\u62c9\u53f8\u7fa4\u4ea6\u5728\u591a\u9805\u7531\u516c\u53f8\u8d0a\u52a9\u7684\u8f49\u79fb\u6027\u4e73\u764c\u81e8\u5e8a\u7814\u7a76\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u53ef\u4f5c\u55ae\u85e5\u6cbb\u7642\u6216\u8207\u5176\u4ed6\u7642\u6cd5\u806f\u5408\u4f7f\u7528\u3002 ELEVATE (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05563220\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">NCT05563220<\/a>) \u662f\u4e00\u9805\u7b2c 1b\/2 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u5206\u5225\u8207\u963f\u57f9\u5229\u897f (alpelisib)\u3001\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\u3001\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u745e\u535a\u897f\u5229 (ribociclib) \u6216\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\u3002 ELECTRA (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05386108\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">NCT05386108<\/a>) \u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u7b2c 1b\/2 \u671f\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u6cbb\u7642 ER+\u3001HER2- \u4e73\u764c\u60a3\u8005\u3002 \u8a72\u7814\u7a76\u7684\u7b2c 2 \u671f\u90e8\u5206\u6703\u8a55\u4f30\u6b64\u6cbb\u7642\u65b9\u6848\u5c0d\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6548\u7528\u3002 ELCIN (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05596409\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">NCT05596409<\/a>) \u662f\u4e00\u9805\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u7528\u65bc\u6cbb\u7642 ER+\u3001HER2- \u665a\u671f \/ \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\uff0c\u9019\u4e9b\u60a3\u8005\u5148\u524d\u66fe\u63a5\u53d7\u904e\u4e00\u81f3\u5169\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\uff0c\u4e26\u4e14\u5728\u8f49\u79fb\u6027\u968e\u6bb5\u672a\u66fe\u4f7f\u7528 CDK4\/6 \u6291\u5236\u5291\u3002 ADELA (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06382948?cond=Breast%20Cancer&amp;term=Elacestrant%20&amp;limit=25&amp;page=1&amp;rank=12\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">NCT06382948<\/a>) \u662f\u4e00\u9805\u7b2c 3 \u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\u7528\u65bc\u6cbb\u7642\u4f34\u6709 ESR1 \u57fa\u56e0\u7a81\u8b8a (ESR1-mut) \u816b\u7624\u7684 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002 ELEGANT (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06492616\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">NCT06492616<\/a>) \u662f\u4e00\u9805\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u76f8\u6bd4\uff0c\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001ER+\u3001HER2- \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548\u3002 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u6b63\u5728\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u6db5\u84cb\u8f49\u79fb\u6027\u4e73\u764c\u53ca\u65e9\u671f\u75be\u75c5\u9818\u57df\u3002<\/p>\n<p>\u82e5\u8981\u532f\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u900f\u904e\u96fb\u90f5 <a href=\"mailto:adverseevents@menarinistemline.com\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">adverseevents@menarinistemline.com<\/a> \u806f\u7d61 Stemline Therapeutics, Inc.\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u8a0a\u5747\u8f09\u65bc <a href=\"https:\/\/stemline.com\/contact\/\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">https:\/\/stemline.com\/contact\/<\/a>\u3002<\/p>\n<p>\u57c3\u62c9\u53f8\u7fa4\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u898b\u65bc <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu#product-info\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu#product-info<\/a><\/p>\n<p><b>\u95dc\u65bc The Menarini Group<\/b><\/p>\n<p>The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff09\u662f\u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u53ca\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 55 \u5104\u7f8e\u5143\uff0c\u50f1\u7528\u903e 17,000 \u540d\u54e1\u5de5\u3002 Menarini \u5c08\u6ce8\u65bc\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80f8\u8154\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u7b49\u7bc4\u7587\u3002 Menarini \u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u884c\u92b7\u5168\u7403 140 \u500b\u570b\u5bb6\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.menarini.com&amp;esheet=53558844&amp;newsitemid=20230920907427&amp;lan=en-US&amp;anchor=www.menarini.com&amp;index=5&amp;md5=7682feaaefe280a649c9a9d8a9e54a2c\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">www.menarini.com<\/a>\u3002<\/p>\n<p><b>\u95dc\u65bc Stemline Therapeutics Inc.<\/b><br \/>Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba Menarini Group \u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u9593\u8655\u65bc\u5546\u696d\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u70ba\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u57c3\u62c9\u53f8\u7fa4\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u7642\u6cd5\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001<i>ESR1<\/i> \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e26\u4e14\u5728\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u75c5\u60c5\u4ecd\u51fa\u73fe\u60e1\u5316\u7684\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\u3002 Stemline \u4ea6\u5728\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u4ed6\u683c\u7d22\u8299 (tagraxofusp-erzs)\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002 \u6b64\u5916\uff0cStemline \u5728\u6b50\u6d32\u92b7\u552e\u585e\u5229\u5c3c\u7d22 (selinexor)\uff0c\u9019\u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 (\u51fa\u53e3\u86cb\u767d 1) \u6291\u5236\u5291\u3002 \u8a72\u516c\u53f8\u4ea6\u5206\u5225\u91dd\u5c0d\u4e73\u764c\u53ca\u8840\u6db2\u60e1\u6027\u816b\u7624\u9069\u61c9\u75c7\uff0c\u9032\u884c\u591a\u9805\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u548c\u4ed6\u683c\u7d22\u8299\u7684\u9069\u61c9\u75c7\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u4e14\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u7576\u4e2d\u5305\u62ec\u591a\u7a2e\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\u3001\u91dd\u5c0d\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u548c\u8840\u6db2\u60e1\u6027\u816b\u7624\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\u3002<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnsbtb1 prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[1] \u672c\u65b0\u805e\u7a3f\u4e2d\u6240\u63d0\u53ca\u7684\u7814\u7a76\u6027\u85e5\u7269\u806f\u5408\u7642\u6cd5\u53ca\u672a\u7d93\u6279\u51c6\u7684\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u8207\u7642\u6548\u5c1a\u672a\u7372\u5f97\u7f8e\u570b\u98df\u54c1\u53ca\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u7684\u8b49\u5be6\u3002<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>ELEVATE \u7814\u7a76\u4e2d\u57c3\u62c9\u53f8\u7fa4&#8230;<\/p>\n","protected":false},"author":16,"featured_media":440461,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-440460","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Menarini Group \u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u767c\u8868\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u4f7f\u7528\u57c3\u62c9\u53f8\u7fa4 (Elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (Capivasertib) \u6cbb\u7642 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u6700\u65b0\u6578\u64da\u3002 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"ELEVATE \u7814\u7a76\u4e2d\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7b2c 1b \u671f\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u5206\u6790\u7d50\u679c\u4ee4\u4eba\u9f13\u821e\uff0c\u76f8\u95dc\u8cc7\u6599\u5c07\u516c\u958b\u767c\u8868\u3002  \u7642\u6548\u6578\u64da\u7a81\u986f\u4e86\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u6709\u671b\u89e3\u6c7a ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u95dc\u9375\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u7576\u4e2d\u5305\u62ec ESR1 \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002  \u516c\u53f8\u4ea6\u5c07\u5206\u4eab\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u8a72\u85e5\u7269\u5728\u8f49\u79fb\u6027\u4e73\u764c\u806f\u5408\u6cbb\u7642\u60c5\u5883\u4e2d\uff0c\u4ee5\u53ca\u65e9\u671f\u4e73\u764c\u55ae\u85e5\u6cbb\u7642\u4e2d\u7684\u61c9\u7528\u6f5b\u529b\u3002  \u50c5\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u5a92\u9ad4\u4f7f\u7528 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042026\u5e745\u670831\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u8207\u8a3a\u65b7\u516c\u53f8 The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff0c\u7c21\u7a31\u300cMenarini\u300d\uff09\u53ca\u5176\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u7c21\u7a31\u300cStemline\u300d\uff09\u5c07\u767c\u8868\u5176\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u63a1\u7528\u57c3\u62c9\u53f8\u7fa4 (elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib) \u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4\u9670\u6027 (HER2-) \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c \u60a3\u8005\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\u3002Stemline \u5c08\u6ce8\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 \u6b64\u5916\uff0c\u4ea6\u6703\u767c\u8868\u5176\u4ed6\u591a\u9805\u6b63\u5728\u9032\u884c\u4e2d\u8a66\u9a57\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u57c3\u62c9\u53f8\u7fa4\u65bc\u4e73\u764c\u5404\u75c5\u7a0b\u968e\u6bb5\u4e2d\uff0c\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642 (endocrine therapy, ET) \u9aa8\u5e79\u85e5\u7269\u7684\u6f5b\u529b\u3002 \u6b64\u7b49\u6578\u64da\u5c07\u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u3002 ELEVATE \u7814\u7a76\u76ee\u7684\u5728\u65bc\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u671f\u671b\u514b\u670d ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u4e26\u4e14\u5728\u4e0d\u8ad6 ESR1 \u7a81\u8b8a\u72c0\u614b\u5982\u4f55\u7684\u60c5\u6cc1\u4e0b\uff0c\u63d0\u5347\u60a3\u8005\u6cbb\u7642\u6210\u679c\u3002 \u7814\u7a76\u5305\u542b\u516d\u7a2e\u6cbb\u7642\u65b9\u6848\uff0c\u5206\u5225\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207 CDK4\/6 \u6291\u5236\u5291\uff08\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u53ca\u745e\u535a\u897f\u5229 (ribociclib)\uff09\uff0c\u4ee5\u53ca PI3K\/AKT\/mTOR \u8a0a\u865f\u50b3\u5c0e\u9014\u5f91\u6291\u5236\u5291\uff08\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u963f\u57f9\u5229\u897f (alpelisib) \u548c\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\uff09\u806f\u5408\u6cbb\u7642\u7684\u7642\u6548\u3002 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u7684 ELEVATE \u7814\u7a76\u7d50\u679c\uff08\u6458\u8981 1098\uff09 \u4e2d\uff0c\u5305\u62ec\u4f86\u81ea\u57c3\u62c9\u53f8\u7fa4 (258-345 \u6beb\u514b) \u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c (320-400 \u6beb\u514b) \u7b2c 1b \u671f\u968a\u5217 (n=31) \u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\uff0c\u9019\u4e9b\u6578\u64da\u986f\u793a\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf (RP2D) \u968a\u5217\u4e2d\uff0c\u60a3\u8005\u5c55\u73fe\u51fa\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7372\u76ca\u3002 \u5728\u7b2c 2 \u968a\u5217 (n=9) \u4e2d\u78ba\u7acb\u7684\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u70ba\u57c3\u62c9\u53f8\u7fa4 345 \u6beb\u514b\uff0c\u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c 320 \u6beb\u514b\uff0c\u6bcf\u65e5\u5169\u6b21\uff08\u63a1 4 \u5929\u7528\u85e5\uff0f3 \u5929\u505c\u85e5\u7684\u65b9\u5f0f\uff09\u3002 \u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u53ef\u8a55\u4f30\u53cd\u61c9\u7684\u60a3\u8005\u4e2d\uff0c\u521d\u6b65\u7642\u6548\u986f\u793a\u75be\u75c5\u63a7\u5236\u7387 (DCR) \u70ba 88.9%\uff0c24 \u9031\u81e8\u5e8a\u7372\u76ca\u7387 (CBR24) \u70ba 66.7%\uff0c\u800c\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR) \u5247\u70ba 33.3%\u3002 \u6240\u6709\u51fa\u73fe\u5ba2\u89c0\u7de9\u89e3\u7387\u7684\u60a3\u8005\u7686\u5177\u6709 ESR1 \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002 \u4e2d\u4f4d\u53cd\u61c9\u6301\u7e8c\u6642\u9593 (mDOR) \u5c1a\u672a\u9054\u5230\u3002 \u00a0\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u7684\u6574\u9ad4\u8a66\u9a57\u4eba\u7fa4\u4e2d\uff0c\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u70ba 11.3 \u500b\u6708\uff0c\u800c\u5177\u6709 ESR1 \u8207 PIK3CA \u5171\u5b58\u7a81\u8b8a\u7684\u60a3\u8005\u5247\u70ba 10.9 \u500b\u6708\u3002 \u6b64\u5916\uff0c\u9019\u4e9b\u521d\u6b65\u7d50\u679c\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8868\u73fe\u8207\u5404\u7d44\u6a19\u9776\u6cbb\u7642\u914d\u5408\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002 Dana-Farber Cancer Institute\uff08\u4e39\u5a1c - \u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff09\u4e73\u817a\u816b\u7624\u79d1\u4e3b\u4efb\uff0c\u91ab\u5b78\u535a\u58eb\u3001\u516c\u5171\u885b\u751f\u78a9\u58eb Sara Tolaney \u8868\u793a\uff1a\u300c\u57c3\u62c9\u53f8\u7fa4\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u806f\u5408\u7642\u6cd5\uff0c\u65e8\u5728\u89e3\u6c7a ER+\/HER2-\u3001PI3K \u8def\u5f91\u767c\u751f\u6539\u8b8a\u7684\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u5c1a\u672a\u7372\u5f97\u6eff\u8db3\u7684\u6cbb\u7642\u9700\u6c42\uff0c\u7279\u5225\u662f\u5728 ESR1 \u8207 PIK3CA \u7a81\u8b8a\u540c\u6642\u51fa\u73fe\u7684\u60c5\u6cc1\u4e0b\u3002\u00a0 \u9019\u4e9b\u4ee4\u4eba\u9f13\u821e\u7684\u521d\u6b65\u6578\u64da\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u5177\u6709\u5ef6\u9577\u81e8\u5e8a\u6548\u76ca\u7684\u6f5b\u529b\uff0c\u800c\u5176\u5b89\u5168\u6027\u4ea6\u5c6c\u53ef\u63a7\uff0c\u7686\u56e0\u5b83\u53ef\u4ee5\u540c\u6642\u91dd\u5c0d ESR1 \u8207 PIK3CA \u7a81\u8b8a\uff0c\u5f9e\u800c\u6709\u53ef\u80fd\u907f\u514d\u5c0d\u6bcf\u500b\u9776\u9ede\u9010\u4e00\u63a1\u7528\u5e8f\u5217\u6cbb\u7642\u7684\u9700\u8981\u3002\u300d Menarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300c\u57fa\u65bc\u6211\u5011\u53bb\u5e74\u5728\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u770b\u5230\u7684\u6578\u64da\uff0c\u6211\u5011\u7e7c\u7e8c\u5c0d\u57c3\u62c9\u53f8\u7fa4\u5728\u8207\u4e0d\u540c\u4f5c\u7528\u6a5f\u5236\u85e5\u7269\u7d44\u6210\u7684\u591a\u7a2e\u806f\u5408\u7642\u6cd5\u4e2d\uff0c\u91dd\u5c0d ER+\/HER2\u2212 \u8f49\u79fb\u6027\u4e73\u764c\u6240\u5c55\u73fe\u51fa\u7684\u6f5b\u5728\u81e8\u5e8a\u6548\u76ca\u611f\u5230\u9f13\u821e\u3002 \u6211\u5011\u7684\u7814\u7a76\u7bc4\u570d\u5ee3\u6cdb\uff0c\u6db5\u84cb\u65e9\u671f\u4e73\u764c\uff0c\u4ee5\u53ca\u591a\u7a2e\u91dd\u5c0d ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u7684\u806f\u5408\u7642\u6cd5\uff08\u5305\u62ec\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u806f\u5408\u7642\u6cd5\uff09\uff0c\u5c55\u73fe\u51fa\u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u6f5b\u5728\u8b8a\u9769\u6027\u6cbb\u7642\u65b9\u6848\u7684\u627f\u8afe\u3002\u300d \u6b64\u5916\uff0c\u5176\u4ed6\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u7684\u6578\u64da\u4ea6\u5c07\u65bc\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u5927\u6703\u4e0a\u516c\u4f48\u3002 \u4ee5\u4e0b\u662f\u5373\u5c07\u8209\u884c\u7c21\u5831\u7684\u5b8c\u6574\u540d\u55ae\uff1a \u7c21\u5831\u6a19\u984c\uff1a\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u6cbb\u7642 ER+\/HER2- \u665a\u671f\u4e73\u764c\u60a3\u8005\uff1aELEVATE \u7814\u7a76\uff08\u4e00\u9805\u7b2c 1b\/2 \u671f\u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\uff09\u7684\u6700\u65b0\u9032\u5c55\u6458\u8981\u7de8\u865f\uff1a1098\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 212 \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1a Wassim McHayleh \u7c21\u5831\u6a19\u984c\uff1aADELA\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u5206\u7d44\u7684\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\uff0c\u5c0d\u6bd4\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5b89\u6170\u5291\u5728\u60a3\u6709 ER+\/HER2- \u665a\u671f\u4e73\u764c\u4e14\u816b\u7624\u5e36\u6709 ESR1 \u7a81\u8b8a\uff0c\u4e26\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642\u9023\u540c CDK4\/6 \u6291\u5236\u5291*# \u5f8c\u75c5\u60c5\u60e1\u5316\u60a3\u8005\u4e2d\u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1154\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 262b \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1a Antonio Llombart-Cussac \u7c21\u5831\u6a19\u984c\uff1aELECTRA\uff1a\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u591a\u4e2d\u5fc3\u3001\u7b2c 1b\/2 \u671f\u7814\u7a76\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u5728\u60a3\u6709\u8166\u90e8\u8f49\u79fb\u7684 ER+\/HER2- \u4e73\u764c\u60a3\u8005\u4e2d\u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1155\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 263a \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aNuhad Ibrahim \u7c21\u5831\u6a19\u984c\uff1aCAPELA\uff1a\u4e00\u9805\u7b2c 2 \u671f\u591a\u4e2d\u5fc3\u958b\u653e\u6a19\u7c64\u96a8\u6a5f\u7814\u7a76\uff0c\u8a55\u4f30\u5361\u57f9\u4ed6\u6ff1 (capecitabine) \u806f\u5408\u57c3\u62c9\u53f8\u7fa4\uff0c\u76f8\u8f03\u65bc\u55ae\u7368\u4f7f\u7528\u5361\u57f9\u4ed6\u6ff1\u6cbb\u7642\u665a\u671f\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u4e73\u764c (TBCRC 070)* \u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1156\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 263b \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aKristina Fanucci \u7c21\u5831\u6a19\u984c\uff1aELEGANT\uff1a\u5728\u4e00\u9805\u5168\u7403\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\u4e2d\uff0c\u6bd4\u8f03\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u7528\u65bc\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548 \u6458\u8981\u7de8\u865f\uff1aTPS1153\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 262a \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aAditya Bardia *\u8868\u793a\u7814\u7a76\u8005\u767c\u8d77\u7814\u7a76\u6216\u5408\u4f5c\u7814\u7a76 #ADELA \u7814\u7a76\u662f\u4e00\u9805\u8207 MEDSIR \u5171\u540c\u8d0a\u52a9\u7684\u95dc\u9375\u6027\u7814\u7a76 \u95dc\u65bc\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u5728\u591a\u9805\u7531\u516c\u53f8\u8d0a\u52a9\u7684\u8f49\u79fb\u6027\u4e73\u764c\u81e8\u5e8a\u7814\u7a76\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u53ef\u4f5c\u55ae\u85e5\u6cbb\u7642\u6216\u8207\u5176\u4ed6\u7642\u6cd5\u806f\u5408\u4f7f\u7528\u3002 ELEVATE (NCT05563220) \u662f\u4e00\u9805\u7b2c 1b\/2 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u5206\u5225\u8207\u963f\u57f9\u5229\u897f (alpelisib)\u3001\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\u3001\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u745e\u535a\u897f\u5229 (ribociclib) \u6216\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\u3002 ELECTRA (NCT05386108) \u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u7b2c 1b\/2 \u671f\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u6cbb\u7642 ER+\u3001HER2- \u4e73\u764c\u60a3\u8005\u3002 \u8a72\u7814\u7a76\u7684\u7b2c 2 \u671f\u90e8\u5206\u6703\u8a55\u4f30\u6b64\u6cbb\u7642\u65b9\u6848\u5c0d\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6548\u7528\u3002 ELCIN (NCT05596409) \u662f\u4e00\u9805\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u7528\u65bc\u6cbb\u7642 ER+\u3001HER2- \u665a\u671f \/ \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\uff0c\u9019\u4e9b\u60a3\u8005\u5148\u524d\u66fe\u63a5\u53d7\u904e\u4e00\u81f3\u5169\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\uff0c\u4e26\u4e14\u5728\u8f49\u79fb\u6027\u968e\u6bb5\u672a\u66fe\u4f7f\u7528 CDK4\/6 \u6291\u5236\u5291\u3002 ADELA (NCT06382948) \u662f\u4e00\u9805\u7b2c 3 \u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\u7528\u65bc\u6cbb\u7642\u4f34\u6709 ESR1 \u57fa\u56e0\u7a81\u8b8a (ESR1-mut) \u816b\u7624\u7684 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002 ELEGANT (NCT06492616) \u662f\u4e00\u9805\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u76f8\u6bd4\uff0c\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001ER+\u3001HER2- \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548\u3002 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u6b63\u5728\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u6db5\u84cb\u8f49\u79fb\u6027\u4e73\u764c\u53ca\u65e9\u671f\u75be\u75c5\u9818\u57df\u3002 \u82e5\u8981\u532f\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u900f\u904e\u96fb\u90f5 adverseevents@menarinistemline.com \u806f\u7d61 Stemline Therapeutics, Inc.\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u8a0a\u5747\u8f09\u65bc https:\/\/stemline.com\/contact\/\u3002 \u57c3\u62c9\u53f8\u7fa4\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u898b\u65bc https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu#product-info \u95dc\u65bc The Menarini Group The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff09\u662f\u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u53ca\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 55 \u5104\u7f8e\u5143\uff0c\u50f1\u7528\u903e 17,000 \u540d\u54e1\u5de5\u3002 Menarini \u5c08\u6ce8\u65bc\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80f8\u8154\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u7b49\u7bc4\u7587\u3002 Menarini \u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u884c\u92b7\u5168\u7403 140 \u500b\u570b\u5bb6\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc Stemline Therapeutics Inc.Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba Menarini Group \u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u9593\u8655\u65bc\u5546\u696d\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u70ba\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u57c3\u62c9\u53f8\u7fa4\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u7642\u6cd5\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001ESR1 \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e26\u4e14\u5728\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u75c5\u60c5\u4ecd\u51fa\u73fe\u60e1\u5316\u7684\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\u3002 Stemline \u4ea6\u5728\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u4ed6\u683c\u7d22\u8299 (tagraxofusp-erzs)\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002 \u6b64\u5916\uff0cStemline \u5728\u6b50\u6d32\u92b7\u552e\u585e\u5229\u5c3c\u7d22 (selinexor)\uff0c\u9019\u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 (\u51fa\u53e3\u86cb\u767d 1) \u6291\u5236\u5291\u3002 \u8a72\u516c\u53f8\u4ea6\u5206\u5225\u91dd\u5c0d\u4e73\u764c\u53ca\u8840\u6db2\u60e1\u6027\u816b\u7624\u9069\u61c9\u75c7\uff0c\u9032\u884c\u591a\u9805\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u548c\u4ed6\u683c\u7d22\u8299\u7684\u9069\u61c9\u75c7\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u4e14\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u7576\u4e2d\u5305\u62ec\u591a\u7a2e\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\u3001\u91dd\u5c0d\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u548c\u8840\u6db2\u60e1\u6027\u816b\u7624\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\u3002           \u672c\u65b0\u805e\u7a3f\u4e2d\u6240\u63d0\u53ca\u7684\u7814\u7a76\u6027\u85e5\u7269\u806f\u5408\u7642\u6cd5\u53ca\u672a\u7d93\u6279\u51c6\u7684\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u8207\u7642\u6548\u5c1a\u672a\u7372\u5f97\u7f8e\u570b\u98df\u54c1\u53ca\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u7684\u8b49\u5be6\u3002        \u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=440460\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Menarini Group \u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u767c\u8868\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u4f7f\u7528\u57c3\u62c9\u53f8\u7fa4 (Elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (Capivasertib) \u6cbb\u7642 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u6700\u65b0\u6578\u64da\u3002 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"ELEVATE \u7814\u7a76\u4e2d\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7b2c 1b \u671f\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u5206\u6790\u7d50\u679c\u4ee4\u4eba\u9f13\u821e\uff0c\u76f8\u95dc\u8cc7\u6599\u5c07\u516c\u958b\u767c\u8868\u3002  \u7642\u6548\u6578\u64da\u7a81\u986f\u4e86\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u6709\u671b\u89e3\u6c7a ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u95dc\u9375\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u7576\u4e2d\u5305\u62ec ESR1 \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002  \u516c\u53f8\u4ea6\u5c07\u5206\u4eab\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u8a72\u85e5\u7269\u5728\u8f49\u79fb\u6027\u4e73\u764c\u806f\u5408\u6cbb\u7642\u60c5\u5883\u4e2d\uff0c\u4ee5\u53ca\u65e9\u671f\u4e73\u764c\u55ae\u85e5\u6cbb\u7642\u4e2d\u7684\u61c9\u7528\u6f5b\u529b\u3002  \u50c5\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u5a92\u9ad4\u4f7f\u7528 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042026\u5e745\u670831\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u8207\u8a3a\u65b7\u516c\u53f8 The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff0c\u7c21\u7a31\u300cMenarini\u300d\uff09\u53ca\u5176\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u7c21\u7a31\u300cStemline\u300d\uff09\u5c07\u767c\u8868\u5176\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u63a1\u7528\u57c3\u62c9\u53f8\u7fa4 (elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib) \u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4\u9670\u6027 (HER2-) \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c \u60a3\u8005\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\u3002Stemline \u5c08\u6ce8\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 \u6b64\u5916\uff0c\u4ea6\u6703\u767c\u8868\u5176\u4ed6\u591a\u9805\u6b63\u5728\u9032\u884c\u4e2d\u8a66\u9a57\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u57c3\u62c9\u53f8\u7fa4\u65bc\u4e73\u764c\u5404\u75c5\u7a0b\u968e\u6bb5\u4e2d\uff0c\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642 (endocrine therapy, ET) \u9aa8\u5e79\u85e5\u7269\u7684\u6f5b\u529b\u3002 \u6b64\u7b49\u6578\u64da\u5c07\u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u3002 ELEVATE \u7814\u7a76\u76ee\u7684\u5728\u65bc\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u671f\u671b\u514b\u670d ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u4e26\u4e14\u5728\u4e0d\u8ad6 ESR1 \u7a81\u8b8a\u72c0\u614b\u5982\u4f55\u7684\u60c5\u6cc1\u4e0b\uff0c\u63d0\u5347\u60a3\u8005\u6cbb\u7642\u6210\u679c\u3002 \u7814\u7a76\u5305\u542b\u516d\u7a2e\u6cbb\u7642\u65b9\u6848\uff0c\u5206\u5225\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207 CDK4\/6 \u6291\u5236\u5291\uff08\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u53ca\u745e\u535a\u897f\u5229 (ribociclib)\uff09\uff0c\u4ee5\u53ca PI3K\/AKT\/mTOR \u8a0a\u865f\u50b3\u5c0e\u9014\u5f91\u6291\u5236\u5291\uff08\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u963f\u57f9\u5229\u897f (alpelisib) \u548c\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\uff09\u806f\u5408\u6cbb\u7642\u7684\u7642\u6548\u3002 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u7684 ELEVATE \u7814\u7a76\u7d50\u679c\uff08\u6458\u8981 1098\uff09 \u4e2d\uff0c\u5305\u62ec\u4f86\u81ea\u57c3\u62c9\u53f8\u7fa4 (258-345 \u6beb\u514b) \u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c (320-400 \u6beb\u514b) \u7b2c 1b \u671f\u968a\u5217 (n=31) \u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\uff0c\u9019\u4e9b\u6578\u64da\u986f\u793a\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf (RP2D) \u968a\u5217\u4e2d\uff0c\u60a3\u8005\u5c55\u73fe\u51fa\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7372\u76ca\u3002 \u5728\u7b2c 2 \u968a\u5217 (n=9) \u4e2d\u78ba\u7acb\u7684\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u70ba\u57c3\u62c9\u53f8\u7fa4 345 \u6beb\u514b\uff0c\u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c 320 \u6beb\u514b\uff0c\u6bcf\u65e5\u5169\u6b21\uff08\u63a1 4 \u5929\u7528\u85e5\uff0f3 \u5929\u505c\u85e5\u7684\u65b9\u5f0f\uff09\u3002 \u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u53ef\u8a55\u4f30\u53cd\u61c9\u7684\u60a3\u8005\u4e2d\uff0c\u521d\u6b65\u7642\u6548\u986f\u793a\u75be\u75c5\u63a7\u5236\u7387 (DCR) \u70ba 88.9%\uff0c24 \u9031\u81e8\u5e8a\u7372\u76ca\u7387 (CBR24) \u70ba 66.7%\uff0c\u800c\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR) \u5247\u70ba 33.3%\u3002 \u6240\u6709\u51fa\u73fe\u5ba2\u89c0\u7de9\u89e3\u7387\u7684\u60a3\u8005\u7686\u5177\u6709 ESR1 \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002 \u4e2d\u4f4d\u53cd\u61c9\u6301\u7e8c\u6642\u9593 (mDOR) \u5c1a\u672a\u9054\u5230\u3002 \u00a0\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u7684\u6574\u9ad4\u8a66\u9a57\u4eba\u7fa4\u4e2d\uff0c\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u70ba 11.3 \u500b\u6708\uff0c\u800c\u5177\u6709 ESR1 \u8207 PIK3CA \u5171\u5b58\u7a81\u8b8a\u7684\u60a3\u8005\u5247\u70ba 10.9 \u500b\u6708\u3002 \u6b64\u5916\uff0c\u9019\u4e9b\u521d\u6b65\u7d50\u679c\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8868\u73fe\u8207\u5404\u7d44\u6a19\u9776\u6cbb\u7642\u914d\u5408\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002 Dana-Farber Cancer Institute\uff08\u4e39\u5a1c - \u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff09\u4e73\u817a\u816b\u7624\u79d1\u4e3b\u4efb\uff0c\u91ab\u5b78\u535a\u58eb\u3001\u516c\u5171\u885b\u751f\u78a9\u58eb Sara Tolaney \u8868\u793a\uff1a\u300c\u57c3\u62c9\u53f8\u7fa4\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u806f\u5408\u7642\u6cd5\uff0c\u65e8\u5728\u89e3\u6c7a ER+\/HER2-\u3001PI3K \u8def\u5f91\u767c\u751f\u6539\u8b8a\u7684\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u5c1a\u672a\u7372\u5f97\u6eff\u8db3\u7684\u6cbb\u7642\u9700\u6c42\uff0c\u7279\u5225\u662f\u5728 ESR1 \u8207 PIK3CA \u7a81\u8b8a\u540c\u6642\u51fa\u73fe\u7684\u60c5\u6cc1\u4e0b\u3002\u00a0 \u9019\u4e9b\u4ee4\u4eba\u9f13\u821e\u7684\u521d\u6b65\u6578\u64da\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u5177\u6709\u5ef6\u9577\u81e8\u5e8a\u6548\u76ca\u7684\u6f5b\u529b\uff0c\u800c\u5176\u5b89\u5168\u6027\u4ea6\u5c6c\u53ef\u63a7\uff0c\u7686\u56e0\u5b83\u53ef\u4ee5\u540c\u6642\u91dd\u5c0d ESR1 \u8207 PIK3CA \u7a81\u8b8a\uff0c\u5f9e\u800c\u6709\u53ef\u80fd\u907f\u514d\u5c0d\u6bcf\u500b\u9776\u9ede\u9010\u4e00\u63a1\u7528\u5e8f\u5217\u6cbb\u7642\u7684\u9700\u8981\u3002\u300d Menarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300c\u57fa\u65bc\u6211\u5011\u53bb\u5e74\u5728\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u770b\u5230\u7684\u6578\u64da\uff0c\u6211\u5011\u7e7c\u7e8c\u5c0d\u57c3\u62c9\u53f8\u7fa4\u5728\u8207\u4e0d\u540c\u4f5c\u7528\u6a5f\u5236\u85e5\u7269\u7d44\u6210\u7684\u591a\u7a2e\u806f\u5408\u7642\u6cd5\u4e2d\uff0c\u91dd\u5c0d ER+\/HER2\u2212 \u8f49\u79fb\u6027\u4e73\u764c\u6240\u5c55\u73fe\u51fa\u7684\u6f5b\u5728\u81e8\u5e8a\u6548\u76ca\u611f\u5230\u9f13\u821e\u3002 \u6211\u5011\u7684\u7814\u7a76\u7bc4\u570d\u5ee3\u6cdb\uff0c\u6db5\u84cb\u65e9\u671f\u4e73\u764c\uff0c\u4ee5\u53ca\u591a\u7a2e\u91dd\u5c0d ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u7684\u806f\u5408\u7642\u6cd5\uff08\u5305\u62ec\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u806f\u5408\u7642\u6cd5\uff09\uff0c\u5c55\u73fe\u51fa\u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u6f5b\u5728\u8b8a\u9769\u6027\u6cbb\u7642\u65b9\u6848\u7684\u627f\u8afe\u3002\u300d \u6b64\u5916\uff0c\u5176\u4ed6\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u7684\u6578\u64da\u4ea6\u5c07\u65bc\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u5927\u6703\u4e0a\u516c\u4f48\u3002 \u4ee5\u4e0b\u662f\u5373\u5c07\u8209\u884c\u7c21\u5831\u7684\u5b8c\u6574\u540d\u55ae\uff1a \u7c21\u5831\u6a19\u984c\uff1a\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u6cbb\u7642 ER+\/HER2- \u665a\u671f\u4e73\u764c\u60a3\u8005\uff1aELEVATE \u7814\u7a76\uff08\u4e00\u9805\u7b2c 1b\/2 \u671f\u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\uff09\u7684\u6700\u65b0\u9032\u5c55\u6458\u8981\u7de8\u865f\uff1a1098\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 212 \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1a Wassim McHayleh \u7c21\u5831\u6a19\u984c\uff1aADELA\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u5206\u7d44\u7684\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\uff0c\u5c0d\u6bd4\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5b89\u6170\u5291\u5728\u60a3\u6709 ER+\/HER2- \u665a\u671f\u4e73\u764c\u4e14\u816b\u7624\u5e36\u6709 ESR1 \u7a81\u8b8a\uff0c\u4e26\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642\u9023\u540c CDK4\/6 \u6291\u5236\u5291*# \u5f8c\u75c5\u60c5\u60e1\u5316\u60a3\u8005\u4e2d\u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1154\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 262b \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1a Antonio Llombart-Cussac \u7c21\u5831\u6a19\u984c\uff1aELECTRA\uff1a\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u591a\u4e2d\u5fc3\u3001\u7b2c 1b\/2 \u671f\u7814\u7a76\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u5728\u60a3\u6709\u8166\u90e8\u8f49\u79fb\u7684 ER+\/HER2- \u4e73\u764c\u60a3\u8005\u4e2d\u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1155\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 263a \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aNuhad Ibrahim \u7c21\u5831\u6a19\u984c\uff1aCAPELA\uff1a\u4e00\u9805\u7b2c 2 \u671f\u591a\u4e2d\u5fc3\u958b\u653e\u6a19\u7c64\u96a8\u6a5f\u7814\u7a76\uff0c\u8a55\u4f30\u5361\u57f9\u4ed6\u6ff1 (capecitabine) \u806f\u5408\u57c3\u62c9\u53f8\u7fa4\uff0c\u76f8\u8f03\u65bc\u55ae\u7368\u4f7f\u7528\u5361\u57f9\u4ed6\u6ff1\u6cbb\u7642\u665a\u671f\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u4e73\u764c (TBCRC 070)* \u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1156\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 263b \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aKristina Fanucci \u7c21\u5831\u6a19\u984c\uff1aELEGANT\uff1a\u5728\u4e00\u9805\u5168\u7403\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\u4e2d\uff0c\u6bd4\u8f03\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u7528\u65bc\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548 \u6458\u8981\u7de8\u865f\uff1aTPS1153\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 262a \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aAditya Bardia *\u8868\u793a\u7814\u7a76\u8005\u767c\u8d77\u7814\u7a76\u6216\u5408\u4f5c\u7814\u7a76 #ADELA \u7814\u7a76\u662f\u4e00\u9805\u8207 MEDSIR \u5171\u540c\u8d0a\u52a9\u7684\u95dc\u9375\u6027\u7814\u7a76 \u95dc\u65bc\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u5728\u591a\u9805\u7531\u516c\u53f8\u8d0a\u52a9\u7684\u8f49\u79fb\u6027\u4e73\u764c\u81e8\u5e8a\u7814\u7a76\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u53ef\u4f5c\u55ae\u85e5\u6cbb\u7642\u6216\u8207\u5176\u4ed6\u7642\u6cd5\u806f\u5408\u4f7f\u7528\u3002 ELEVATE (NCT05563220) \u662f\u4e00\u9805\u7b2c 1b\/2 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u5206\u5225\u8207\u963f\u57f9\u5229\u897f (alpelisib)\u3001\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\u3001\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u745e\u535a\u897f\u5229 (ribociclib) \u6216\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\u3002 ELECTRA (NCT05386108) \u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u7b2c 1b\/2 \u671f\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u6cbb\u7642 ER+\u3001HER2- \u4e73\u764c\u60a3\u8005\u3002 \u8a72\u7814\u7a76\u7684\u7b2c 2 \u671f\u90e8\u5206\u6703\u8a55\u4f30\u6b64\u6cbb\u7642\u65b9\u6848\u5c0d\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6548\u7528\u3002 ELCIN (NCT05596409) \u662f\u4e00\u9805\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u7528\u65bc\u6cbb\u7642 ER+\u3001HER2- \u665a\u671f \/ \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\uff0c\u9019\u4e9b\u60a3\u8005\u5148\u524d\u66fe\u63a5\u53d7\u904e\u4e00\u81f3\u5169\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\uff0c\u4e26\u4e14\u5728\u8f49\u79fb\u6027\u968e\u6bb5\u672a\u66fe\u4f7f\u7528 CDK4\/6 \u6291\u5236\u5291\u3002 ADELA (NCT06382948) \u662f\u4e00\u9805\u7b2c 3 \u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\u7528\u65bc\u6cbb\u7642\u4f34\u6709 ESR1 \u57fa\u56e0\u7a81\u8b8a (ESR1-mut) \u816b\u7624\u7684 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002 ELEGANT (NCT06492616) \u662f\u4e00\u9805\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u76f8\u6bd4\uff0c\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001ER+\u3001HER2- \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548\u3002 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u6b63\u5728\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u6db5\u84cb\u8f49\u79fb\u6027\u4e73\u764c\u53ca\u65e9\u671f\u75be\u75c5\u9818\u57df\u3002 \u82e5\u8981\u532f\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u900f\u904e\u96fb\u90f5 adverseevents@menarinistemline.com \u806f\u7d61 Stemline Therapeutics, Inc.\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u8a0a\u5747\u8f09\u65bc https:\/\/stemline.com\/contact\/\u3002 \u57c3\u62c9\u53f8\u7fa4\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u898b\u65bc https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu#product-info \u95dc\u65bc The Menarini Group The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff09\u662f\u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u53ca\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 55 \u5104\u7f8e\u5143\uff0c\u50f1\u7528\u903e 17,000 \u540d\u54e1\u5de5\u3002 Menarini \u5c08\u6ce8\u65bc\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80f8\u8154\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u7b49\u7bc4\u7587\u3002 Menarini \u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u884c\u92b7\u5168\u7403 140 \u500b\u570b\u5bb6\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc Stemline Therapeutics Inc.Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba Menarini Group \u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u9593\u8655\u65bc\u5546\u696d\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u70ba\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u57c3\u62c9\u53f8\u7fa4\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u7642\u6cd5\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001ESR1 \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e26\u4e14\u5728\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u75c5\u60c5\u4ecd\u51fa\u73fe\u60e1\u5316\u7684\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\u3002 Stemline \u4ea6\u5728\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u4ed6\u683c\u7d22\u8299 (tagraxofusp-erzs)\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002 \u6b64\u5916\uff0cStemline \u5728\u6b50\u6d32\u92b7\u552e\u585e\u5229\u5c3c\u7d22 (selinexor)\uff0c\u9019\u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 (\u51fa\u53e3\u86cb\u767d 1) \u6291\u5236\u5291\u3002 \u8a72\u516c\u53f8\u4ea6\u5206\u5225\u91dd\u5c0d\u4e73\u764c\u53ca\u8840\u6db2\u60e1\u6027\u816b\u7624\u9069\u61c9\u75c7\uff0c\u9032\u884c\u591a\u9805\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u548c\u4ed6\u683c\u7d22\u8299\u7684\u9069\u61c9\u75c7\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u4e14\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u7576\u4e2d\u5305\u62ec\u591a\u7a2e\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\u3001\u91dd\u5c0d\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u548c\u8840\u6db2\u60e1\u6027\u816b\u7624\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\u3002           \u672c\u65b0\u805e\u7a3f\u4e2d\u6240\u63d0\u53ca\u7684\u7814\u7a76\u6027\u85e5\u7269\u806f\u5408\u7642\u6cd5\u53ca\u672a\u7d93\u6279\u51c6\u7684\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u8207\u7642\u6548\u5c1a\u672a\u7372\u5f97\u7f8e\u570b\u98df\u54c1\u53ca\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u7684\u8b49\u5be6\u3002        \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=440460\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-30T19:25:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1990\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=440460#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=440460\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"Menarini Group \u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u767c\u8868\u7b2c 1b\\\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u4f7f\u7528\u57c3\u62c9\u53f8\u7fa4 (Elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (Capivasertib) \u6cbb\u7642 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u6700\u65b0\u6578\u64da\u3002\",\"datePublished\":\"2026-05-30T19:25:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=440460\"},\"wordCount\":238,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=440460#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=440460\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=440460\",\"name\":\"Menarini Group \u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u767c\u8868\u7b2c 1b\\\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u4f7f\u7528\u57c3\u62c9\u53f8\u7fa4 (Elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (Capivasertib) \u6cbb\u7642 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u6700\u65b0\u6578\u64da\u3002 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=440460#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=440460#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg\",\"datePublished\":\"2026-05-30T19:25:00+00:00\",\"description\":\"ELEVATE \u7814\u7a76\u4e2d\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7b2c 1b \u671f\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u5206\u6790\u7d50\u679c\u4ee4\u4eba\u9f13\u821e\uff0c\u76f8\u95dc\u8cc7\u6599\u5c07\u516c\u958b\u767c\u8868\u3002 \u7642\u6548\u6578\u64da\u7a81\u986f\u4e86\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u6709\u671b\u89e3\u6c7a ER+\\\/HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u95dc\u9375\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u7576\u4e2d\u5305\u62ec ESR1 \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002 \u516c\u53f8\u4ea6\u5c07\u5206\u4eab\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u8a72\u85e5\u7269\u5728\u8f49\u79fb\u6027\u4e73\u764c\u806f\u5408\u6cbb\u7642\u60c5\u5883\u4e2d\uff0c\u4ee5\u53ca\u65e9\u671f\u4e73\u764c\u55ae\u85e5\u6cbb\u7642\u4e2d\u7684\u61c9\u7528\u6f5b\u529b\u3002 \u50c5\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u5a92\u9ad4\u4f7f\u7528 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042026\u5e745\u670831\u65e5 \\\/\u7f8e\u901a\u793e\\\/ -- \u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u8207\u8a3a\u65b7\u516c\u53f8 The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff0c\u7c21\u7a31\u300cMenarini\u300d\uff09\u53ca\u5176\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u7c21\u7a31\u300cStemline\u300d\uff09\u5c07\u767c\u8868\u5176\u7b2c 1b\\\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u63a1\u7528\u57c3\u62c9\u53f8\u7fa4 (elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib) \u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4\u9670\u6027 (HER2-) \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c \u60a3\u8005\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\u3002Stemline \u5c08\u6ce8\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 \u6b64\u5916\uff0c\u4ea6\u6703\u767c\u8868\u5176\u4ed6\u591a\u9805\u6b63\u5728\u9032\u884c\u4e2d\u8a66\u9a57\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u57c3\u62c9\u53f8\u7fa4\u65bc\u4e73\u764c\u5404\u75c5\u7a0b\u968e\u6bb5\u4e2d\uff0c\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642 (endocrine therapy, ET) \u9aa8\u5e79\u85e5\u7269\u7684\u6f5b\u529b\u3002 \u6b64\u7b49\u6578\u64da\u5c07\u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u3002 ELEVATE \u7814\u7a76\u76ee\u7684\u5728\u65bc\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u671f\u671b\u514b\u670d ER+\\\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u4e26\u4e14\u5728\u4e0d\u8ad6 ESR1 \u7a81\u8b8a\u72c0\u614b\u5982\u4f55\u7684\u60c5\u6cc1\u4e0b\uff0c\u63d0\u5347\u60a3\u8005\u6cbb\u7642\u6210\u679c\u3002 \u7814\u7a76\u5305\u542b\u516d\u7a2e\u6cbb\u7642\u65b9\u6848\uff0c\u5206\u5225\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207 CDK4\\\/6 \u6291\u5236\u5291\uff08\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u53ca\u745e\u535a\u897f\u5229 (ribociclib)\uff09\uff0c\u4ee5\u53ca PI3K\\\/AKT\\\/mTOR \u8a0a\u865f\u50b3\u5c0e\u9014\u5f91\u6291\u5236\u5291\uff08\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u963f\u57f9\u5229\u897f (alpelisib) \u548c\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\uff09\u806f\u5408\u6cbb\u7642\u7684\u7642\u6548\u3002 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u7684 ELEVATE \u7814\u7a76\u7d50\u679c\uff08\u6458\u8981 1098\uff09 \u4e2d\uff0c\u5305\u62ec\u4f86\u81ea\u57c3\u62c9\u53f8\u7fa4 (258-345 \u6beb\u514b) \u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c (320-400 \u6beb\u514b) \u7b2c 1b \u671f\u968a\u5217 (n=31) \u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\uff0c\u9019\u4e9b\u6578\u64da\u986f\u793a\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf (RP2D) \u968a\u5217\u4e2d\uff0c\u60a3\u8005\u5c55\u73fe\u51fa\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7372\u76ca\u3002 \u5728\u7b2c 2 \u968a\u5217 (n=9) \u4e2d\u78ba\u7acb\u7684\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u70ba\u57c3\u62c9\u53f8\u7fa4 345 \u6beb\u514b\uff0c\u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c 320 \u6beb\u514b\uff0c\u6bcf\u65e5\u5169\u6b21\uff08\u63a1 4 \u5929\u7528\u85e5\uff0f3 \u5929\u505c\u85e5\u7684\u65b9\u5f0f\uff09\u3002 \u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u53ef\u8a55\u4f30\u53cd\u61c9\u7684\u60a3\u8005\u4e2d\uff0c\u521d\u6b65\u7642\u6548\u986f\u793a\u75be\u75c5\u63a7\u5236\u7387 (DCR) \u70ba 88.9%\uff0c24 \u9031\u81e8\u5e8a\u7372\u76ca\u7387 (CBR24) \u70ba 66.7%\uff0c\u800c\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR) \u5247\u70ba 33.3%\u3002 \u6240\u6709\u51fa\u73fe\u5ba2\u89c0\u7de9\u89e3\u7387\u7684\u60a3\u8005\u7686\u5177\u6709 ESR1 \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002 \u4e2d\u4f4d\u53cd\u61c9\u6301\u7e8c\u6642\u9593 (mDOR) \u5c1a\u672a\u9054\u5230\u3002 \u00a0\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u7684\u6574\u9ad4\u8a66\u9a57\u4eba\u7fa4\u4e2d\uff0c\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u70ba 11.3 \u500b\u6708\uff0c\u800c\u5177\u6709 ESR1 \u8207 PIK3CA \u5171\u5b58\u7a81\u8b8a\u7684\u60a3\u8005\u5247\u70ba 10.9 \u500b\u6708\u3002 \u6b64\u5916\uff0c\u9019\u4e9b\u521d\u6b65\u7d50\u679c\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8868\u73fe\u8207\u5404\u7d44\u6a19\u9776\u6cbb\u7642\u914d\u5408\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002 Dana-Farber Cancer Institute\uff08\u4e39\u5a1c - \u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff09\u4e73\u817a\u816b\u7624\u79d1\u4e3b\u4efb\uff0c\u91ab\u5b78\u535a\u58eb\u3001\u516c\u5171\u885b\u751f\u78a9\u58eb Sara Tolaney \u8868\u793a\uff1a\u300c\u57c3\u62c9\u53f8\u7fa4\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u806f\u5408\u7642\u6cd5\uff0c\u65e8\u5728\u89e3\u6c7a ER+\\\/HER2-\u3001PI3K \u8def\u5f91\u767c\u751f\u6539\u8b8a\u7684\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u5c1a\u672a\u7372\u5f97\u6eff\u8db3\u7684\u6cbb\u7642\u9700\u6c42\uff0c\u7279\u5225\u662f\u5728 ESR1 \u8207 PIK3CA \u7a81\u8b8a\u540c\u6642\u51fa\u73fe\u7684\u60c5\u6cc1\u4e0b\u3002\u00a0 \u9019\u4e9b\u4ee4\u4eba\u9f13\u821e\u7684\u521d\u6b65\u6578\u64da\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u5177\u6709\u5ef6\u9577\u81e8\u5e8a\u6548\u76ca\u7684\u6f5b\u529b\uff0c\u800c\u5176\u5b89\u5168\u6027\u4ea6\u5c6c\u53ef\u63a7\uff0c\u7686\u56e0\u5b83\u53ef\u4ee5\u540c\u6642\u91dd\u5c0d ESR1 \u8207 PIK3CA \u7a81\u8b8a\uff0c\u5f9e\u800c\u6709\u53ef\u80fd\u907f\u514d\u5c0d\u6bcf\u500b\u9776\u9ede\u9010\u4e00\u63a1\u7528\u5e8f\u5217\u6cbb\u7642\u7684\u9700\u8981\u3002\u300d Menarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300c\u57fa\u65bc\u6211\u5011\u53bb\u5e74\u5728\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u770b\u5230\u7684\u6578\u64da\uff0c\u6211\u5011\u7e7c\u7e8c\u5c0d\u57c3\u62c9\u53f8\u7fa4\u5728\u8207\u4e0d\u540c\u4f5c\u7528\u6a5f\u5236\u85e5\u7269\u7d44\u6210\u7684\u591a\u7a2e\u806f\u5408\u7642\u6cd5\u4e2d\uff0c\u91dd\u5c0d ER+\\\/HER2\u2212 \u8f49\u79fb\u6027\u4e73\u764c\u6240\u5c55\u73fe\u51fa\u7684\u6f5b\u5728\u81e8\u5e8a\u6548\u76ca\u611f\u5230\u9f13\u821e\u3002 \u6211\u5011\u7684\u7814\u7a76\u7bc4\u570d\u5ee3\u6cdb\uff0c\u6db5\u84cb\u65e9\u671f\u4e73\u764c\uff0c\u4ee5\u53ca\u591a\u7a2e\u91dd\u5c0d ER+\\\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u7684\u806f\u5408\u7642\u6cd5\uff08\u5305\u62ec\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u806f\u5408\u7642\u6cd5\uff09\uff0c\u5c55\u73fe\u51fa\u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u6f5b\u5728\u8b8a\u9769\u6027\u6cbb\u7642\u65b9\u6848\u7684\u627f\u8afe\u3002\u300d \u6b64\u5916\uff0c\u5176\u4ed6\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u7684\u6578\u64da\u4ea6\u5c07\u65bc\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u5927\u6703\u4e0a\u516c\u4f48\u3002 \u4ee5\u4e0b\u662f\u5373\u5c07\u8209\u884c\u7c21\u5831\u7684\u5b8c\u6574\u540d\u55ae\uff1a \u7c21\u5831\u6a19\u984c\uff1a\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u6cbb\u7642 ER+\\\/HER2- \u665a\u671f\u4e73\u764c\u60a3\u8005\uff1aELEVATE \u7814\u7a76\uff08\u4e00\u9805\u7b2c 1b\\\/2 \u671f\u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\uff09\u7684\u6700\u65b0\u9032\u5c55\u6458\u8981\u7de8\u865f\uff1a1098\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 212 \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1a Wassim McHayleh \u7c21\u5831\u6a19\u984c\uff1aADELA\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u5206\u7d44\u7684\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\uff0c\u5c0d\u6bd4\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5b89\u6170\u5291\u5728\u60a3\u6709 ER+\\\/HER2- \u665a\u671f\u4e73\u764c\u4e14\u816b\u7624\u5e36\u6709 ESR1 \u7a81\u8b8a\uff0c\u4e26\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642\u9023\u540c CDK4\\\/6 \u6291\u5236\u5291*# \u5f8c\u75c5\u60c5\u60e1\u5316\u60a3\u8005\u4e2d\u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1154\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 262b \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1a Antonio Llombart-Cussac \u7c21\u5831\u6a19\u984c\uff1aELECTRA\uff1a\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u591a\u4e2d\u5fc3\u3001\u7b2c 1b\\\/2 \u671f\u7814\u7a76\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u5728\u60a3\u6709\u8166\u90e8\u8f49\u79fb\u7684 ER+\\\/HER2- \u4e73\u764c\u60a3\u8005\u4e2d\u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1155\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 263a \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aNuhad Ibrahim \u7c21\u5831\u6a19\u984c\uff1aCAPELA\uff1a\u4e00\u9805\u7b2c 2 \u671f\u591a\u4e2d\u5fc3\u958b\u653e\u6a19\u7c64\u96a8\u6a5f\u7814\u7a76\uff0c\u8a55\u4f30\u5361\u57f9\u4ed6\u6ff1 (capecitabine) \u806f\u5408\u57c3\u62c9\u53f8\u7fa4\uff0c\u76f8\u8f03\u65bc\u55ae\u7368\u4f7f\u7528\u5361\u57f9\u4ed6\u6ff1\u6cbb\u7642\u665a\u671f\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u4e73\u764c (TBCRC 070)* \u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1156\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 263b \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aKristina Fanucci \u7c21\u5831\u6a19\u984c\uff1aELEGANT\uff1a\u5728\u4e00\u9805\u5168\u7403\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\u4e2d\uff0c\u6bd4\u8f03\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u7528\u65bc\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548 \u6458\u8981\u7de8\u865f\uff1aTPS1153\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 262a \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aAditya Bardia *\u8868\u793a\u7814\u7a76\u8005\u767c\u8d77\u7814\u7a76\u6216\u5408\u4f5c\u7814\u7a76 #ADELA \u7814\u7a76\u662f\u4e00\u9805\u8207 MEDSIR \u5171\u540c\u8d0a\u52a9\u7684\u95dc\u9375\u6027\u7814\u7a76 \u95dc\u65bc\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u5728\u591a\u9805\u7531\u516c\u53f8\u8d0a\u52a9\u7684\u8f49\u79fb\u6027\u4e73\u764c\u81e8\u5e8a\u7814\u7a76\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u53ef\u4f5c\u55ae\u85e5\u6cbb\u7642\u6216\u8207\u5176\u4ed6\u7642\u6cd5\u806f\u5408\u4f7f\u7528\u3002 ELEVATE (NCT05563220) \u662f\u4e00\u9805\u7b2c 1b\\\/2 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u5206\u5225\u8207\u963f\u57f9\u5229\u897f (alpelisib)\u3001\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\u3001\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u745e\u535a\u897f\u5229 (ribociclib) \u6216\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\u3002 ELECTRA (NCT05386108) \u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u7b2c 1b\\\/2 \u671f\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u6cbb\u7642 ER+\u3001HER2- \u4e73\u764c\u60a3\u8005\u3002 \u8a72\u7814\u7a76\u7684\u7b2c 2 \u671f\u90e8\u5206\u6703\u8a55\u4f30\u6b64\u6cbb\u7642\u65b9\u6848\u5c0d\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6548\u7528\u3002 ELCIN (NCT05596409) \u662f\u4e00\u9805\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u7528\u65bc\u6cbb\u7642 ER+\u3001HER2- \u665a\u671f \\\/ \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\uff0c\u9019\u4e9b\u60a3\u8005\u5148\u524d\u66fe\u63a5\u53d7\u904e\u4e00\u81f3\u5169\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\uff0c\u4e26\u4e14\u5728\u8f49\u79fb\u6027\u968e\u6bb5\u672a\u66fe\u4f7f\u7528 CDK4\\\/6 \u6291\u5236\u5291\u3002 ADELA (NCT06382948) \u662f\u4e00\u9805\u7b2c 3 \u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\u7528\u65bc\u6cbb\u7642\u4f34\u6709 ESR1 \u57fa\u56e0\u7a81\u8b8a (ESR1-mut) \u816b\u7624\u7684 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002 ELEGANT (NCT06492616) \u662f\u4e00\u9805\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u76f8\u6bd4\uff0c\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001ER+\u3001HER2- \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548\u3002 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u6b63\u5728\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u6db5\u84cb\u8f49\u79fb\u6027\u4e73\u764c\u53ca\u65e9\u671f\u75be\u75c5\u9818\u57df\u3002 \u82e5\u8981\u532f\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u900f\u904e\u96fb\u90f5 adverseevents@menarinistemline.com \u806f\u7d61 Stemline Therapeutics, Inc.\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u8a0a\u5747\u8f09\u65bc https:\\\/\\\/stemline.com\\\/contact\\\/\u3002 \u57c3\u62c9\u53f8\u7fa4\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u898b\u65bc https:\\\/\\\/www.ema.europa.eu\\\/en\\\/medicines\\\/human\\\/EPAR\\\/orserdu#product-info \u95dc\u65bc The Menarini Group The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff09\u662f\u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u53ca\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 55 \u5104\u7f8e\u5143\uff0c\u50f1\u7528\u903e 17,000 \u540d\u54e1\u5de5\u3002 Menarini \u5c08\u6ce8\u65bc\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80f8\u8154\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u7b49\u7bc4\u7587\u3002 Menarini \u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u884c\u92b7\u5168\u7403 140 \u500b\u570b\u5bb6\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc Stemline Therapeutics Inc.Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba Menarini Group \u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u9593\u8655\u65bc\u5546\u696d\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u70ba\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u57c3\u62c9\u53f8\u7fa4\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u7642\u6cd5\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001ESR1 \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e26\u4e14\u5728\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u75c5\u60c5\u4ecd\u51fa\u73fe\u60e1\u5316\u7684\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\u3002 Stemline \u4ea6\u5728\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u4ed6\u683c\u7d22\u8299 (tagraxofusp-erzs)\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002 \u6b64\u5916\uff0cStemline \u5728\u6b50\u6d32\u92b7\u552e\u585e\u5229\u5c3c\u7d22 (selinexor)\uff0c\u9019\u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 (\u51fa\u53e3\u86cb\u767d 1) \u6291\u5236\u5291\u3002 \u8a72\u516c\u53f8\u4ea6\u5206\u5225\u91dd\u5c0d\u4e73\u764c\u53ca\u8840\u6db2\u60e1\u6027\u816b\u7624\u9069\u61c9\u75c7\uff0c\u9032\u884c\u591a\u9805\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u548c\u4ed6\u683c\u7d22\u8299\u7684\u9069\u61c9\u75c7\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u4e14\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u7576\u4e2d\u5305\u62ec\u591a\u7a2e\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\u3001\u91dd\u5c0d\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u548c\u8840\u6db2\u60e1\u6027\u816b\u7624\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\u3002 \u672c\u65b0\u805e\u7a3f\u4e2d\u6240\u63d0\u53ca\u7684\u7814\u7a76\u6027\u85e5\u7269\u806f\u5408\u7642\u6cd5\u53ca\u672a\u7d93\u6279\u51c6\u7684\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u8207\u7642\u6548\u5c1a\u672a\u7372\u5f97\u7f8e\u570b\u98df\u54c1\u53ca\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u7684\u8b49\u5be6\u3002 \u00a0\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=440460#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=440460\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=440460#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg\",\"width\":400,\"height\":121},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=440460#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Menarini Group \u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u767c\u8868\u7b2c 1b\\\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u4f7f\u7528\u57c3\u62c9\u53f8\u7fa4 (Elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (Capivasertib) \u6cbb\u7642 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u6700\u65b0\u6578\u64da\u3002\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Menarini Group \u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u767c\u8868\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u4f7f\u7528\u57c3\u62c9\u53f8\u7fa4 (Elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (Capivasertib) \u6cbb\u7642 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u6700\u65b0\u6578\u64da\u3002 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"ELEVATE \u7814\u7a76\u4e2d\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7b2c 1b \u671f\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u5206\u6790\u7d50\u679c\u4ee4\u4eba\u9f13\u821e\uff0c\u76f8\u95dc\u8cc7\u6599\u5c07\u516c\u958b\u767c\u8868\u3002  \u7642\u6548\u6578\u64da\u7a81\u986f\u4e86\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u6709\u671b\u89e3\u6c7a ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u95dc\u9375\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u7576\u4e2d\u5305\u62ec ESR1 \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002  \u516c\u53f8\u4ea6\u5c07\u5206\u4eab\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u8a72\u85e5\u7269\u5728\u8f49\u79fb\u6027\u4e73\u764c\u806f\u5408\u6cbb\u7642\u60c5\u5883\u4e2d\uff0c\u4ee5\u53ca\u65e9\u671f\u4e73\u764c\u55ae\u85e5\u6cbb\u7642\u4e2d\u7684\u61c9\u7528\u6f5b\u529b\u3002  \u50c5\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u5a92\u9ad4\u4f7f\u7528 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042026\u5e745\u670831\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u8207\u8a3a\u65b7\u516c\u53f8 The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff0c\u7c21\u7a31\u300cMenarini\u300d\uff09\u53ca\u5176\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u7c21\u7a31\u300cStemline\u300d\uff09\u5c07\u767c\u8868\u5176\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u63a1\u7528\u57c3\u62c9\u53f8\u7fa4 (elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib) \u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4\u9670\u6027 (HER2-) \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c \u60a3\u8005\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\u3002Stemline \u5c08\u6ce8\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 \u6b64\u5916\uff0c\u4ea6\u6703\u767c\u8868\u5176\u4ed6\u591a\u9805\u6b63\u5728\u9032\u884c\u4e2d\u8a66\u9a57\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u57c3\u62c9\u53f8\u7fa4\u65bc\u4e73\u764c\u5404\u75c5\u7a0b\u968e\u6bb5\u4e2d\uff0c\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642 (endocrine therapy, ET) \u9aa8\u5e79\u85e5\u7269\u7684\u6f5b\u529b\u3002 \u6b64\u7b49\u6578\u64da\u5c07\u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u3002 ELEVATE \u7814\u7a76\u76ee\u7684\u5728\u65bc\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u671f\u671b\u514b\u670d ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u4e26\u4e14\u5728\u4e0d\u8ad6 ESR1 \u7a81\u8b8a\u72c0\u614b\u5982\u4f55\u7684\u60c5\u6cc1\u4e0b\uff0c\u63d0\u5347\u60a3\u8005\u6cbb\u7642\u6210\u679c\u3002 \u7814\u7a76\u5305\u542b\u516d\u7a2e\u6cbb\u7642\u65b9\u6848\uff0c\u5206\u5225\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207 CDK4\/6 \u6291\u5236\u5291\uff08\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u53ca\u745e\u535a\u897f\u5229 (ribociclib)\uff09\uff0c\u4ee5\u53ca PI3K\/AKT\/mTOR \u8a0a\u865f\u50b3\u5c0e\u9014\u5f91\u6291\u5236\u5291\uff08\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u963f\u57f9\u5229\u897f (alpelisib) \u548c\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\uff09\u806f\u5408\u6cbb\u7642\u7684\u7642\u6548\u3002 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u7684 ELEVATE \u7814\u7a76\u7d50\u679c\uff08\u6458\u8981 1098\uff09 \u4e2d\uff0c\u5305\u62ec\u4f86\u81ea\u57c3\u62c9\u53f8\u7fa4 (258-345 \u6beb\u514b) \u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c (320-400 \u6beb\u514b) \u7b2c 1b \u671f\u968a\u5217 (n=31) \u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\uff0c\u9019\u4e9b\u6578\u64da\u986f\u793a\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf (RP2D) \u968a\u5217\u4e2d\uff0c\u60a3\u8005\u5c55\u73fe\u51fa\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7372\u76ca\u3002 \u5728\u7b2c 2 \u968a\u5217 (n=9) \u4e2d\u78ba\u7acb\u7684\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u70ba\u57c3\u62c9\u53f8\u7fa4 345 \u6beb\u514b\uff0c\u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c 320 \u6beb\u514b\uff0c\u6bcf\u65e5\u5169\u6b21\uff08\u63a1 4 \u5929\u7528\u85e5\uff0f3 \u5929\u505c\u85e5\u7684\u65b9\u5f0f\uff09\u3002 \u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u53ef\u8a55\u4f30\u53cd\u61c9\u7684\u60a3\u8005\u4e2d\uff0c\u521d\u6b65\u7642\u6548\u986f\u793a\u75be\u75c5\u63a7\u5236\u7387 (DCR) \u70ba 88.9%\uff0c24 \u9031\u81e8\u5e8a\u7372\u76ca\u7387 (CBR24) \u70ba 66.7%\uff0c\u800c\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR) \u5247\u70ba 33.3%\u3002 \u6240\u6709\u51fa\u73fe\u5ba2\u89c0\u7de9\u89e3\u7387\u7684\u60a3\u8005\u7686\u5177\u6709 ESR1 \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002 \u4e2d\u4f4d\u53cd\u61c9\u6301\u7e8c\u6642\u9593 (mDOR) \u5c1a\u672a\u9054\u5230\u3002 \u00a0\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u7684\u6574\u9ad4\u8a66\u9a57\u4eba\u7fa4\u4e2d\uff0c\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u70ba 11.3 \u500b\u6708\uff0c\u800c\u5177\u6709 ESR1 \u8207 PIK3CA \u5171\u5b58\u7a81\u8b8a\u7684\u60a3\u8005\u5247\u70ba 10.9 \u500b\u6708\u3002 \u6b64\u5916\uff0c\u9019\u4e9b\u521d\u6b65\u7d50\u679c\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8868\u73fe\u8207\u5404\u7d44\u6a19\u9776\u6cbb\u7642\u914d\u5408\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002 Dana-Farber Cancer Institute\uff08\u4e39\u5a1c - \u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff09\u4e73\u817a\u816b\u7624\u79d1\u4e3b\u4efb\uff0c\u91ab\u5b78\u535a\u58eb\u3001\u516c\u5171\u885b\u751f\u78a9\u58eb Sara Tolaney \u8868\u793a\uff1a\u300c\u57c3\u62c9\u53f8\u7fa4\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u806f\u5408\u7642\u6cd5\uff0c\u65e8\u5728\u89e3\u6c7a ER+\/HER2-\u3001PI3K \u8def\u5f91\u767c\u751f\u6539\u8b8a\u7684\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u5c1a\u672a\u7372\u5f97\u6eff\u8db3\u7684\u6cbb\u7642\u9700\u6c42\uff0c\u7279\u5225\u662f\u5728 ESR1 \u8207 PIK3CA \u7a81\u8b8a\u540c\u6642\u51fa\u73fe\u7684\u60c5\u6cc1\u4e0b\u3002\u00a0 \u9019\u4e9b\u4ee4\u4eba\u9f13\u821e\u7684\u521d\u6b65\u6578\u64da\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u5177\u6709\u5ef6\u9577\u81e8\u5e8a\u6548\u76ca\u7684\u6f5b\u529b\uff0c\u800c\u5176\u5b89\u5168\u6027\u4ea6\u5c6c\u53ef\u63a7\uff0c\u7686\u56e0\u5b83\u53ef\u4ee5\u540c\u6642\u91dd\u5c0d ESR1 \u8207 PIK3CA \u7a81\u8b8a\uff0c\u5f9e\u800c\u6709\u53ef\u80fd\u907f\u514d\u5c0d\u6bcf\u500b\u9776\u9ede\u9010\u4e00\u63a1\u7528\u5e8f\u5217\u6cbb\u7642\u7684\u9700\u8981\u3002\u300d Menarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300c\u57fa\u65bc\u6211\u5011\u53bb\u5e74\u5728\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u770b\u5230\u7684\u6578\u64da\uff0c\u6211\u5011\u7e7c\u7e8c\u5c0d\u57c3\u62c9\u53f8\u7fa4\u5728\u8207\u4e0d\u540c\u4f5c\u7528\u6a5f\u5236\u85e5\u7269\u7d44\u6210\u7684\u591a\u7a2e\u806f\u5408\u7642\u6cd5\u4e2d\uff0c\u91dd\u5c0d ER+\/HER2\u2212 \u8f49\u79fb\u6027\u4e73\u764c\u6240\u5c55\u73fe\u51fa\u7684\u6f5b\u5728\u81e8\u5e8a\u6548\u76ca\u611f\u5230\u9f13\u821e\u3002 \u6211\u5011\u7684\u7814\u7a76\u7bc4\u570d\u5ee3\u6cdb\uff0c\u6db5\u84cb\u65e9\u671f\u4e73\u764c\uff0c\u4ee5\u53ca\u591a\u7a2e\u91dd\u5c0d ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u7684\u806f\u5408\u7642\u6cd5\uff08\u5305\u62ec\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u806f\u5408\u7642\u6cd5\uff09\uff0c\u5c55\u73fe\u51fa\u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u6f5b\u5728\u8b8a\u9769\u6027\u6cbb\u7642\u65b9\u6848\u7684\u627f\u8afe\u3002\u300d \u6b64\u5916\uff0c\u5176\u4ed6\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u7684\u6578\u64da\u4ea6\u5c07\u65bc\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u5927\u6703\u4e0a\u516c\u4f48\u3002 \u4ee5\u4e0b\u662f\u5373\u5c07\u8209\u884c\u7c21\u5831\u7684\u5b8c\u6574\u540d\u55ae\uff1a \u7c21\u5831\u6a19\u984c\uff1a\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u6cbb\u7642 ER+\/HER2- \u665a\u671f\u4e73\u764c\u60a3\u8005\uff1aELEVATE \u7814\u7a76\uff08\u4e00\u9805\u7b2c 1b\/2 \u671f\u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\uff09\u7684\u6700\u65b0\u9032\u5c55\u6458\u8981\u7de8\u865f\uff1a1098\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 212 \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1a Wassim McHayleh \u7c21\u5831\u6a19\u984c\uff1aADELA\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u5206\u7d44\u7684\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\uff0c\u5c0d\u6bd4\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5b89\u6170\u5291\u5728\u60a3\u6709 ER+\/HER2- \u665a\u671f\u4e73\u764c\u4e14\u816b\u7624\u5e36\u6709 ESR1 \u7a81\u8b8a\uff0c\u4e26\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642\u9023\u540c CDK4\/6 \u6291\u5236\u5291*# \u5f8c\u75c5\u60c5\u60e1\u5316\u60a3\u8005\u4e2d\u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1154\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 262b \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1a Antonio Llombart-Cussac \u7c21\u5831\u6a19\u984c\uff1aELECTRA\uff1a\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u591a\u4e2d\u5fc3\u3001\u7b2c 1b\/2 \u671f\u7814\u7a76\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u5728\u60a3\u6709\u8166\u90e8\u8f49\u79fb\u7684 ER+\/HER2- \u4e73\u764c\u60a3\u8005\u4e2d\u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1155\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 263a \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aNuhad Ibrahim \u7c21\u5831\u6a19\u984c\uff1aCAPELA\uff1a\u4e00\u9805\u7b2c 2 \u671f\u591a\u4e2d\u5fc3\u958b\u653e\u6a19\u7c64\u96a8\u6a5f\u7814\u7a76\uff0c\u8a55\u4f30\u5361\u57f9\u4ed6\u6ff1 (capecitabine) \u806f\u5408\u57c3\u62c9\u53f8\u7fa4\uff0c\u76f8\u8f03\u65bc\u55ae\u7368\u4f7f\u7528\u5361\u57f9\u4ed6\u6ff1\u6cbb\u7642\u665a\u671f\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u4e73\u764c (TBCRC 070)* \u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1156\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 263b \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aKristina Fanucci \u7c21\u5831\u6a19\u984c\uff1aELEGANT\uff1a\u5728\u4e00\u9805\u5168\u7403\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\u4e2d\uff0c\u6bd4\u8f03\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u7528\u65bc\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548 \u6458\u8981\u7de8\u865f\uff1aTPS1153\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 262a \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aAditya Bardia *\u8868\u793a\u7814\u7a76\u8005\u767c\u8d77\u7814\u7a76\u6216\u5408\u4f5c\u7814\u7a76 #ADELA \u7814\u7a76\u662f\u4e00\u9805\u8207 MEDSIR \u5171\u540c\u8d0a\u52a9\u7684\u95dc\u9375\u6027\u7814\u7a76 \u95dc\u65bc\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u5728\u591a\u9805\u7531\u516c\u53f8\u8d0a\u52a9\u7684\u8f49\u79fb\u6027\u4e73\u764c\u81e8\u5e8a\u7814\u7a76\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u53ef\u4f5c\u55ae\u85e5\u6cbb\u7642\u6216\u8207\u5176\u4ed6\u7642\u6cd5\u806f\u5408\u4f7f\u7528\u3002 ELEVATE (NCT05563220) \u662f\u4e00\u9805\u7b2c 1b\/2 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u5206\u5225\u8207\u963f\u57f9\u5229\u897f (alpelisib)\u3001\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\u3001\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u745e\u535a\u897f\u5229 (ribociclib) \u6216\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\u3002 ELECTRA (NCT05386108) \u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u7b2c 1b\/2 \u671f\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u6cbb\u7642 ER+\u3001HER2- \u4e73\u764c\u60a3\u8005\u3002 \u8a72\u7814\u7a76\u7684\u7b2c 2 \u671f\u90e8\u5206\u6703\u8a55\u4f30\u6b64\u6cbb\u7642\u65b9\u6848\u5c0d\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6548\u7528\u3002 ELCIN (NCT05596409) \u662f\u4e00\u9805\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u7528\u65bc\u6cbb\u7642 ER+\u3001HER2- \u665a\u671f \/ \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\uff0c\u9019\u4e9b\u60a3\u8005\u5148\u524d\u66fe\u63a5\u53d7\u904e\u4e00\u81f3\u5169\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\uff0c\u4e26\u4e14\u5728\u8f49\u79fb\u6027\u968e\u6bb5\u672a\u66fe\u4f7f\u7528 CDK4\/6 \u6291\u5236\u5291\u3002 ADELA (NCT06382948) \u662f\u4e00\u9805\u7b2c 3 \u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\u7528\u65bc\u6cbb\u7642\u4f34\u6709 ESR1 \u57fa\u56e0\u7a81\u8b8a (ESR1-mut) \u816b\u7624\u7684 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002 ELEGANT (NCT06492616) \u662f\u4e00\u9805\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u76f8\u6bd4\uff0c\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001ER+\u3001HER2- \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548\u3002 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u6b63\u5728\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u6db5\u84cb\u8f49\u79fb\u6027\u4e73\u764c\u53ca\u65e9\u671f\u75be\u75c5\u9818\u57df\u3002 \u82e5\u8981\u532f\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u900f\u904e\u96fb\u90f5 adverseevents@menarinistemline.com \u806f\u7d61 Stemline Therapeutics, Inc.\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u8a0a\u5747\u8f09\u65bc https:\/\/stemline.com\/contact\/\u3002 \u57c3\u62c9\u53f8\u7fa4\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u898b\u65bc https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu#product-info \u95dc\u65bc The Menarini Group The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff09\u662f\u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u53ca\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 55 \u5104\u7f8e\u5143\uff0c\u50f1\u7528\u903e 17,000 \u540d\u54e1\u5de5\u3002 Menarini \u5c08\u6ce8\u65bc\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80f8\u8154\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u7b49\u7bc4\u7587\u3002 Menarini \u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u884c\u92b7\u5168\u7403 140 \u500b\u570b\u5bb6\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc Stemline Therapeutics Inc.Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba Menarini Group \u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u9593\u8655\u65bc\u5546\u696d\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u70ba\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u57c3\u62c9\u53f8\u7fa4\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u7642\u6cd5\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001ESR1 \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e26\u4e14\u5728\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u75c5\u60c5\u4ecd\u51fa\u73fe\u60e1\u5316\u7684\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\u3002 Stemline \u4ea6\u5728\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u4ed6\u683c\u7d22\u8299 (tagraxofusp-erzs)\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002 \u6b64\u5916\uff0cStemline \u5728\u6b50\u6d32\u92b7\u552e\u585e\u5229\u5c3c\u7d22 (selinexor)\uff0c\u9019\u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 (\u51fa\u53e3\u86cb\u767d 1) \u6291\u5236\u5291\u3002 \u8a72\u516c\u53f8\u4ea6\u5206\u5225\u91dd\u5c0d\u4e73\u764c\u53ca\u8840\u6db2\u60e1\u6027\u816b\u7624\u9069\u61c9\u75c7\uff0c\u9032\u884c\u591a\u9805\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u548c\u4ed6\u683c\u7d22\u8299\u7684\u9069\u61c9\u75c7\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u4e14\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u7576\u4e2d\u5305\u62ec\u591a\u7a2e\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\u3001\u91dd\u5c0d\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u548c\u8840\u6db2\u60e1\u6027\u816b\u7624\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\u3002           \u672c\u65b0\u805e\u7a3f\u4e2d\u6240\u63d0\u53ca\u7684\u7814\u7a76\u6027\u85e5\u7269\u806f\u5408\u7642\u6cd5\u53ca\u672a\u7d93\u6279\u51c6\u7684\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u8207\u7642\u6548\u5c1a\u672a\u7372\u5f97\u7f8e\u570b\u98df\u54c1\u53ca\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u7684\u8b49\u5be6\u3002        \u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=440460","og_locale":"zh_TW","og_type":"article","og_title":"Menarini Group \u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u767c\u8868\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u4f7f\u7528\u57c3\u62c9\u53f8\u7fa4 (Elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (Capivasertib) \u6cbb\u7642 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u6700\u65b0\u6578\u64da\u3002 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"ELEVATE \u7814\u7a76\u4e2d\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7b2c 1b \u671f\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u5206\u6790\u7d50\u679c\u4ee4\u4eba\u9f13\u821e\uff0c\u76f8\u95dc\u8cc7\u6599\u5c07\u516c\u958b\u767c\u8868\u3002  \u7642\u6548\u6578\u64da\u7a81\u986f\u4e86\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u6709\u671b\u89e3\u6c7a ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u95dc\u9375\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u7576\u4e2d\u5305\u62ec ESR1 \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002  \u516c\u53f8\u4ea6\u5c07\u5206\u4eab\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u8a72\u85e5\u7269\u5728\u8f49\u79fb\u6027\u4e73\u764c\u806f\u5408\u6cbb\u7642\u60c5\u5883\u4e2d\uff0c\u4ee5\u53ca\u65e9\u671f\u4e73\u764c\u55ae\u85e5\u6cbb\u7642\u4e2d\u7684\u61c9\u7528\u6f5b\u529b\u3002  \u50c5\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u5a92\u9ad4\u4f7f\u7528 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042026\u5e745\u670831\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u8207\u8a3a\u65b7\u516c\u53f8 The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff0c\u7c21\u7a31\u300cMenarini\u300d\uff09\u53ca\u5176\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u7c21\u7a31\u300cStemline\u300d\uff09\u5c07\u767c\u8868\u5176\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u63a1\u7528\u57c3\u62c9\u53f8\u7fa4 (elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib) \u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4\u9670\u6027 (HER2-) \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c \u60a3\u8005\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\u3002Stemline \u5c08\u6ce8\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 \u6b64\u5916\uff0c\u4ea6\u6703\u767c\u8868\u5176\u4ed6\u591a\u9805\u6b63\u5728\u9032\u884c\u4e2d\u8a66\u9a57\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u57c3\u62c9\u53f8\u7fa4\u65bc\u4e73\u764c\u5404\u75c5\u7a0b\u968e\u6bb5\u4e2d\uff0c\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642 (endocrine therapy, ET) \u9aa8\u5e79\u85e5\u7269\u7684\u6f5b\u529b\u3002 \u6b64\u7b49\u6578\u64da\u5c07\u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u3002 ELEVATE \u7814\u7a76\u76ee\u7684\u5728\u65bc\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u671f\u671b\u514b\u670d ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u4e26\u4e14\u5728\u4e0d\u8ad6 ESR1 \u7a81\u8b8a\u72c0\u614b\u5982\u4f55\u7684\u60c5\u6cc1\u4e0b\uff0c\u63d0\u5347\u60a3\u8005\u6cbb\u7642\u6210\u679c\u3002 \u7814\u7a76\u5305\u542b\u516d\u7a2e\u6cbb\u7642\u65b9\u6848\uff0c\u5206\u5225\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207 CDK4\/6 \u6291\u5236\u5291\uff08\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u53ca\u745e\u535a\u897f\u5229 (ribociclib)\uff09\uff0c\u4ee5\u53ca PI3K\/AKT\/mTOR \u8a0a\u865f\u50b3\u5c0e\u9014\u5f91\u6291\u5236\u5291\uff08\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u963f\u57f9\u5229\u897f (alpelisib) \u548c\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\uff09\u806f\u5408\u6cbb\u7642\u7684\u7642\u6548\u3002 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u7684 ELEVATE \u7814\u7a76\u7d50\u679c\uff08\u6458\u8981 1098\uff09 \u4e2d\uff0c\u5305\u62ec\u4f86\u81ea\u57c3\u62c9\u53f8\u7fa4 (258-345 \u6beb\u514b) \u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c (320-400 \u6beb\u514b) \u7b2c 1b \u671f\u968a\u5217 (n=31) \u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\uff0c\u9019\u4e9b\u6578\u64da\u986f\u793a\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf (RP2D) \u968a\u5217\u4e2d\uff0c\u60a3\u8005\u5c55\u73fe\u51fa\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7372\u76ca\u3002 \u5728\u7b2c 2 \u968a\u5217 (n=9) \u4e2d\u78ba\u7acb\u7684\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u70ba\u57c3\u62c9\u53f8\u7fa4 345 \u6beb\u514b\uff0c\u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c 320 \u6beb\u514b\uff0c\u6bcf\u65e5\u5169\u6b21\uff08\u63a1 4 \u5929\u7528\u85e5\uff0f3 \u5929\u505c\u85e5\u7684\u65b9\u5f0f\uff09\u3002 \u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u53ef\u8a55\u4f30\u53cd\u61c9\u7684\u60a3\u8005\u4e2d\uff0c\u521d\u6b65\u7642\u6548\u986f\u793a\u75be\u75c5\u63a7\u5236\u7387 (DCR) \u70ba 88.9%\uff0c24 \u9031\u81e8\u5e8a\u7372\u76ca\u7387 (CBR24) \u70ba 66.7%\uff0c\u800c\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR) \u5247\u70ba 33.3%\u3002 \u6240\u6709\u51fa\u73fe\u5ba2\u89c0\u7de9\u89e3\u7387\u7684\u60a3\u8005\u7686\u5177\u6709 ESR1 \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002 \u4e2d\u4f4d\u53cd\u61c9\u6301\u7e8c\u6642\u9593 (mDOR) \u5c1a\u672a\u9054\u5230\u3002 \u00a0\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u7684\u6574\u9ad4\u8a66\u9a57\u4eba\u7fa4\u4e2d\uff0c\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u70ba 11.3 \u500b\u6708\uff0c\u800c\u5177\u6709 ESR1 \u8207 PIK3CA \u5171\u5b58\u7a81\u8b8a\u7684\u60a3\u8005\u5247\u70ba 10.9 \u500b\u6708\u3002 \u6b64\u5916\uff0c\u9019\u4e9b\u521d\u6b65\u7d50\u679c\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8868\u73fe\u8207\u5404\u7d44\u6a19\u9776\u6cbb\u7642\u914d\u5408\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002 Dana-Farber Cancer Institute\uff08\u4e39\u5a1c - \u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff09\u4e73\u817a\u816b\u7624\u79d1\u4e3b\u4efb\uff0c\u91ab\u5b78\u535a\u58eb\u3001\u516c\u5171\u885b\u751f\u78a9\u58eb Sara Tolaney \u8868\u793a\uff1a\u300c\u57c3\u62c9\u53f8\u7fa4\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u806f\u5408\u7642\u6cd5\uff0c\u65e8\u5728\u89e3\u6c7a ER+\/HER2-\u3001PI3K \u8def\u5f91\u767c\u751f\u6539\u8b8a\u7684\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u5c1a\u672a\u7372\u5f97\u6eff\u8db3\u7684\u6cbb\u7642\u9700\u6c42\uff0c\u7279\u5225\u662f\u5728 ESR1 \u8207 PIK3CA \u7a81\u8b8a\u540c\u6642\u51fa\u73fe\u7684\u60c5\u6cc1\u4e0b\u3002\u00a0 \u9019\u4e9b\u4ee4\u4eba\u9f13\u821e\u7684\u521d\u6b65\u6578\u64da\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u5177\u6709\u5ef6\u9577\u81e8\u5e8a\u6548\u76ca\u7684\u6f5b\u529b\uff0c\u800c\u5176\u5b89\u5168\u6027\u4ea6\u5c6c\u53ef\u63a7\uff0c\u7686\u56e0\u5b83\u53ef\u4ee5\u540c\u6642\u91dd\u5c0d ESR1 \u8207 PIK3CA \u7a81\u8b8a\uff0c\u5f9e\u800c\u6709\u53ef\u80fd\u907f\u514d\u5c0d\u6bcf\u500b\u9776\u9ede\u9010\u4e00\u63a1\u7528\u5e8f\u5217\u6cbb\u7642\u7684\u9700\u8981\u3002\u300d Menarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300c\u57fa\u65bc\u6211\u5011\u53bb\u5e74\u5728\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u770b\u5230\u7684\u6578\u64da\uff0c\u6211\u5011\u7e7c\u7e8c\u5c0d\u57c3\u62c9\u53f8\u7fa4\u5728\u8207\u4e0d\u540c\u4f5c\u7528\u6a5f\u5236\u85e5\u7269\u7d44\u6210\u7684\u591a\u7a2e\u806f\u5408\u7642\u6cd5\u4e2d\uff0c\u91dd\u5c0d ER+\/HER2\u2212 \u8f49\u79fb\u6027\u4e73\u764c\u6240\u5c55\u73fe\u51fa\u7684\u6f5b\u5728\u81e8\u5e8a\u6548\u76ca\u611f\u5230\u9f13\u821e\u3002 \u6211\u5011\u7684\u7814\u7a76\u7bc4\u570d\u5ee3\u6cdb\uff0c\u6db5\u84cb\u65e9\u671f\u4e73\u764c\uff0c\u4ee5\u53ca\u591a\u7a2e\u91dd\u5c0d ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u7684\u806f\u5408\u7642\u6cd5\uff08\u5305\u62ec\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u806f\u5408\u7642\u6cd5\uff09\uff0c\u5c55\u73fe\u51fa\u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u6f5b\u5728\u8b8a\u9769\u6027\u6cbb\u7642\u65b9\u6848\u7684\u627f\u8afe\u3002\u300d \u6b64\u5916\uff0c\u5176\u4ed6\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u7684\u6578\u64da\u4ea6\u5c07\u65bc\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u5927\u6703\u4e0a\u516c\u4f48\u3002 \u4ee5\u4e0b\u662f\u5373\u5c07\u8209\u884c\u7c21\u5831\u7684\u5b8c\u6574\u540d\u55ae\uff1a \u7c21\u5831\u6a19\u984c\uff1a\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u6cbb\u7642 ER+\/HER2- \u665a\u671f\u4e73\u764c\u60a3\u8005\uff1aELEVATE \u7814\u7a76\uff08\u4e00\u9805\u7b2c 1b\/2 \u671f\u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\uff09\u7684\u6700\u65b0\u9032\u5c55\u6458\u8981\u7de8\u865f\uff1a1098\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 212 \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1a Wassim McHayleh \u7c21\u5831\u6a19\u984c\uff1aADELA\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u5206\u7d44\u7684\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\uff0c\u5c0d\u6bd4\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5b89\u6170\u5291\u5728\u60a3\u6709 ER+\/HER2- \u665a\u671f\u4e73\u764c\u4e14\u816b\u7624\u5e36\u6709 ESR1 \u7a81\u8b8a\uff0c\u4e26\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642\u9023\u540c CDK4\/6 \u6291\u5236\u5291*# \u5f8c\u75c5\u60c5\u60e1\u5316\u60a3\u8005\u4e2d\u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1154\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 262b \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1a Antonio Llombart-Cussac \u7c21\u5831\u6a19\u984c\uff1aELECTRA\uff1a\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u591a\u4e2d\u5fc3\u3001\u7b2c 1b\/2 \u671f\u7814\u7a76\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u5728\u60a3\u6709\u8166\u90e8\u8f49\u79fb\u7684 ER+\/HER2- \u4e73\u764c\u60a3\u8005\u4e2d\u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1155\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 263a \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aNuhad Ibrahim \u7c21\u5831\u6a19\u984c\uff1aCAPELA\uff1a\u4e00\u9805\u7b2c 2 \u671f\u591a\u4e2d\u5fc3\u958b\u653e\u6a19\u7c64\u96a8\u6a5f\u7814\u7a76\uff0c\u8a55\u4f30\u5361\u57f9\u4ed6\u6ff1 (capecitabine) \u806f\u5408\u57c3\u62c9\u53f8\u7fa4\uff0c\u76f8\u8f03\u65bc\u55ae\u7368\u4f7f\u7528\u5361\u57f9\u4ed6\u6ff1\u6cbb\u7642\u665a\u671f\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u4e73\u764c (TBCRC 070)* \u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1156\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 263b \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aKristina Fanucci \u7c21\u5831\u6a19\u984c\uff1aELEGANT\uff1a\u5728\u4e00\u9805\u5168\u7403\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\u4e2d\uff0c\u6bd4\u8f03\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u7528\u65bc\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548 \u6458\u8981\u7de8\u865f\uff1aTPS1153\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 262a \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aAditya Bardia *\u8868\u793a\u7814\u7a76\u8005\u767c\u8d77\u7814\u7a76\u6216\u5408\u4f5c\u7814\u7a76 #ADELA \u7814\u7a76\u662f\u4e00\u9805\u8207 MEDSIR \u5171\u540c\u8d0a\u52a9\u7684\u95dc\u9375\u6027\u7814\u7a76 \u95dc\u65bc\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u5728\u591a\u9805\u7531\u516c\u53f8\u8d0a\u52a9\u7684\u8f49\u79fb\u6027\u4e73\u764c\u81e8\u5e8a\u7814\u7a76\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u53ef\u4f5c\u55ae\u85e5\u6cbb\u7642\u6216\u8207\u5176\u4ed6\u7642\u6cd5\u806f\u5408\u4f7f\u7528\u3002 ELEVATE (NCT05563220) \u662f\u4e00\u9805\u7b2c 1b\/2 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u5206\u5225\u8207\u963f\u57f9\u5229\u897f (alpelisib)\u3001\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\u3001\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u745e\u535a\u897f\u5229 (ribociclib) \u6216\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\u3002 ELECTRA (NCT05386108) \u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u7b2c 1b\/2 \u671f\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u6cbb\u7642 ER+\u3001HER2- \u4e73\u764c\u60a3\u8005\u3002 \u8a72\u7814\u7a76\u7684\u7b2c 2 \u671f\u90e8\u5206\u6703\u8a55\u4f30\u6b64\u6cbb\u7642\u65b9\u6848\u5c0d\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6548\u7528\u3002 ELCIN (NCT05596409) \u662f\u4e00\u9805\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u7528\u65bc\u6cbb\u7642 ER+\u3001HER2- \u665a\u671f \/ \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\uff0c\u9019\u4e9b\u60a3\u8005\u5148\u524d\u66fe\u63a5\u53d7\u904e\u4e00\u81f3\u5169\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\uff0c\u4e26\u4e14\u5728\u8f49\u79fb\u6027\u968e\u6bb5\u672a\u66fe\u4f7f\u7528 CDK4\/6 \u6291\u5236\u5291\u3002 ADELA (NCT06382948) \u662f\u4e00\u9805\u7b2c 3 \u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\u7528\u65bc\u6cbb\u7642\u4f34\u6709 ESR1 \u57fa\u56e0\u7a81\u8b8a (ESR1-mut) \u816b\u7624\u7684 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002 ELEGANT (NCT06492616) \u662f\u4e00\u9805\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u76f8\u6bd4\uff0c\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001ER+\u3001HER2- \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548\u3002 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u6b63\u5728\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u6db5\u84cb\u8f49\u79fb\u6027\u4e73\u764c\u53ca\u65e9\u671f\u75be\u75c5\u9818\u57df\u3002 \u82e5\u8981\u532f\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u900f\u904e\u96fb\u90f5 adverseevents@menarinistemline.com \u806f\u7d61 Stemline Therapeutics, Inc.\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u8a0a\u5747\u8f09\u65bc https:\/\/stemline.com\/contact\/\u3002 \u57c3\u62c9\u53f8\u7fa4\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u898b\u65bc https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu#product-info \u95dc\u65bc The Menarini Group The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff09\u662f\u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u53ca\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 55 \u5104\u7f8e\u5143\uff0c\u50f1\u7528\u903e 17,000 \u540d\u54e1\u5de5\u3002 Menarini \u5c08\u6ce8\u65bc\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80f8\u8154\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u7b49\u7bc4\u7587\u3002 Menarini \u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u884c\u92b7\u5168\u7403 140 \u500b\u570b\u5bb6\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc Stemline Therapeutics Inc.Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba Menarini Group \u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u9593\u8655\u65bc\u5546\u696d\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u70ba\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u57c3\u62c9\u53f8\u7fa4\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u7642\u6cd5\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001ESR1 \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e26\u4e14\u5728\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u75c5\u60c5\u4ecd\u51fa\u73fe\u60e1\u5316\u7684\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\u3002 Stemline \u4ea6\u5728\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u4ed6\u683c\u7d22\u8299 (tagraxofusp-erzs)\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002 \u6b64\u5916\uff0cStemline \u5728\u6b50\u6d32\u92b7\u552e\u585e\u5229\u5c3c\u7d22 (selinexor)\uff0c\u9019\u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 (\u51fa\u53e3\u86cb\u767d 1) \u6291\u5236\u5291\u3002 \u8a72\u516c\u53f8\u4ea6\u5206\u5225\u91dd\u5c0d\u4e73\u764c\u53ca\u8840\u6db2\u60e1\u6027\u816b\u7624\u9069\u61c9\u75c7\uff0c\u9032\u884c\u591a\u9805\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u548c\u4ed6\u683c\u7d22\u8299\u7684\u9069\u61c9\u75c7\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u4e14\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u7576\u4e2d\u5305\u62ec\u591a\u7a2e\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\u3001\u91dd\u5c0d\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u548c\u8840\u6db2\u60e1\u6027\u816b\u7624\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\u3002           \u672c\u65b0\u805e\u7a3f\u4e2d\u6240\u63d0\u53ca\u7684\u7814\u7a76\u6027\u85e5\u7269\u806f\u5408\u7642\u6cd5\u53ca\u672a\u7d93\u6279\u51c6\u7684\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u8207\u7642\u6548\u5c1a\u672a\u7372\u5f97\u7f8e\u570b\u98df\u54c1\u53ca\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u7684\u8b49\u5be6\u3002        \u00a0","og_url":"https:\/\/pingtungtimes.com.tw\/?p=440460","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2026-05-30T19:25:00+00:00","og_image":[{"width":3000,"height":1990,"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","type":"image\/jpeg"}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"1 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=440460#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=440460"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"Menarini Group \u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u767c\u8868\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u4f7f\u7528\u57c3\u62c9\u53f8\u7fa4 (Elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (Capivasertib) \u6cbb\u7642 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u6700\u65b0\u6578\u64da\u3002","datePublished":"2026-05-30T19:25:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=440460"},"wordCount":238,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=440460#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/05\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=440460","url":"https:\/\/pingtungtimes.com.tw\/?p=440460","name":"Menarini Group \u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u767c\u8868\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u4f7f\u7528\u57c3\u62c9\u53f8\u7fa4 (Elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (Capivasertib) \u6cbb\u7642 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u6700\u65b0\u6578\u64da\u3002 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=440460#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=440460#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/05\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg","datePublished":"2026-05-30T19:25:00+00:00","description":"ELEVATE \u7814\u7a76\u4e2d\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7b2c 1b \u671f\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u5206\u6790\u7d50\u679c\u4ee4\u4eba\u9f13\u821e\uff0c\u76f8\u95dc\u8cc7\u6599\u5c07\u516c\u958b\u767c\u8868\u3002 \u7642\u6548\u6578\u64da\u7a81\u986f\u4e86\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u6cbb\u7642\u65b9\u6848\uff0c\u6709\u671b\u89e3\u6c7a ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u95dc\u9375\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u7576\u4e2d\u5305\u62ec ESR1 \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002 \u516c\u53f8\u4ea6\u5c07\u5206\u4eab\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u8a72\u85e5\u7269\u5728\u8f49\u79fb\u6027\u4e73\u764c\u806f\u5408\u6cbb\u7642\u60c5\u5883\u4e2d\uff0c\u4ee5\u53ca\u65e9\u671f\u4e73\u764c\u55ae\u85e5\u6cbb\u7642\u4e2d\u7684\u61c9\u7528\u6f5b\u529b\u3002 \u50c5\u4f9b\u91ab\u7642\u53ca\u88fd\u85e5\u696d\u5a92\u9ad4\u4f7f\u7528 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042026\u5e745\u670831\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u8207\u8a3a\u65b7\u516c\u53f8 The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff0c\u7c21\u7a31\u300cMenarini\u300d\uff09\u53ca\u5176\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u7c21\u7a31\u300cStemline\u300d\uff09\u5c07\u767c\u8868\u5176\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u63a1\u7528\u57c3\u62c9\u53f8\u7fa4 (elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib) \u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4\u9670\u6027 (HER2-) \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c \u60a3\u8005\u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\u3002Stemline \u5c08\u6ce8\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 \u6b64\u5916\uff0c\u4ea6\u6703\u767c\u8868\u5176\u4ed6\u591a\u9805\u6b63\u5728\u9032\u884c\u4e2d\u8a66\u9a57\u7684\u6700\u65b0\u9032\u5c55\uff0c\u7a81\u986f\u57c3\u62c9\u53f8\u7fa4\u65bc\u4e73\u764c\u5404\u75c5\u7a0b\u968e\u6bb5\u4e2d\uff0c\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642 (endocrine therapy, ET) \u9aa8\u5e79\u85e5\u7269\u7684\u6f5b\u529b\u3002 \u6b64\u7b49\u6578\u64da\u5c07\u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u3002 ELEVATE \u7814\u7a76\u76ee\u7684\u5728\u65bc\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u671f\u671b\u514b\u670d ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6027\u6a5f\u5236\uff0c\u4e26\u4e14\u5728\u4e0d\u8ad6 ESR1 \u7a81\u8b8a\u72c0\u614b\u5982\u4f55\u7684\u60c5\u6cc1\u4e0b\uff0c\u63d0\u5347\u60a3\u8005\u6cbb\u7642\u6210\u679c\u3002 \u7814\u7a76\u5305\u542b\u516d\u7a2e\u6cbb\u7642\u65b9\u6848\uff0c\u5206\u5225\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207 CDK4\/6 \u6291\u5236\u5291\uff08\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u53ca\u745e\u535a\u897f\u5229 (ribociclib)\uff09\uff0c\u4ee5\u53ca PI3K\/AKT\/mTOR \u8a0a\u865f\u50b3\u5c0e\u9014\u5f91\u6291\u5236\u5291\uff08\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u963f\u57f9\u5229\u897f (alpelisib) \u548c\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\uff09\u806f\u5408\u6cbb\u7642\u7684\u7642\u6548\u3002 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703\u9031\u5e74\u5927\u6703\u4e0a\u516c\u4f48\u7684 ELEVATE \u7814\u7a76\u7d50\u679c\uff08\u6458\u8981 1098\uff09 \u4e2d\uff0c\u5305\u62ec\u4f86\u81ea\u57c3\u62c9\u53f8\u7fa4 (258-345 \u6beb\u514b) \u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c (320-400 \u6beb\u514b) \u7b2c 1b \u671f\u968a\u5217 (n=31) \u7684\u5b89\u5168\u6027\u53ca\u521d\u6b65\u7642\u6548\u6578\u64da\uff0c\u9019\u4e9b\u6578\u64da\u986f\u793a\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf (RP2D) \u968a\u5217\u4e2d\uff0c\u60a3\u8005\u5c55\u73fe\u51fa\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7372\u76ca\u3002 \u5728\u7b2c 2 \u968a\u5217 (n=9) \u4e2d\u78ba\u7acb\u7684\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u70ba\u57c3\u62c9\u53f8\u7fa4 345 \u6beb\u514b\uff0c\u914d\u5408\u5361\u5e15\u585e\u66ff\u5c3c 320 \u6beb\u514b\uff0c\u6bcf\u65e5\u5169\u6b21\uff08\u63a1 4 \u5929\u7528\u85e5\uff0f3 \u5929\u505c\u85e5\u7684\u65b9\u5f0f\uff09\u3002 \u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u53ef\u8a55\u4f30\u53cd\u61c9\u7684\u60a3\u8005\u4e2d\uff0c\u521d\u6b65\u7642\u6548\u986f\u793a\u75be\u75c5\u63a7\u5236\u7387 (DCR) \u70ba 88.9%\uff0c24 \u9031\u81e8\u5e8a\u7372\u76ca\u7387 (CBR24) \u70ba 66.7%\uff0c\u800c\u5ba2\u89c0\u7de9\u89e3\u7387 (ORR) \u5247\u70ba 33.3%\u3002 \u6240\u6709\u51fa\u73fe\u5ba2\u89c0\u7de9\u89e3\u7387\u7684\u60a3\u8005\u7686\u5177\u6709 ESR1 \u8207 PIK3CA \u7684\u5171\u5b58\u7a81\u8b8a\u3002 \u4e2d\u4f4d\u53cd\u61c9\u6301\u7e8c\u6642\u9593 (mDOR) \u5c1a\u672a\u9054\u5230\u3002 \u00a0\u5728\u5efa\u8b70\u7b2c 2 \u671f\u5291\u91cf\u7684\u6574\u9ad4\u8a66\u9a57\u4eba\u7fa4\u4e2d\uff0c\u521d\u6b65\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u70ba 11.3 \u500b\u6708\uff0c\u800c\u5177\u6709 ESR1 \u8207 PIK3CA \u5171\u5b58\u7a81\u8b8a\u7684\u60a3\u8005\u5247\u70ba 10.9 \u500b\u6708\u3002 \u6b64\u5916\uff0c\u9019\u4e9b\u521d\u6b65\u7d50\u679c\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8868\u73fe\u8207\u5404\u7d44\u6a19\u9776\u6cbb\u7642\u914d\u5408\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002 Dana-Farber Cancer Institute\uff08\u4e39\u5a1c - \u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff09\u4e73\u817a\u816b\u7624\u79d1\u4e3b\u4efb\uff0c\u91ab\u5b78\u535a\u58eb\u3001\u516c\u5171\u885b\u751f\u78a9\u58eb Sara Tolaney \u8868\u793a\uff1a\u300c\u57c3\u62c9\u53f8\u7fa4\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u806f\u5408\u7642\u6cd5\uff0c\u65e8\u5728\u89e3\u6c7a ER+\/HER2-\u3001PI3K \u8def\u5f91\u767c\u751f\u6539\u8b8a\u7684\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u5c1a\u672a\u7372\u5f97\u6eff\u8db3\u7684\u6cbb\u7642\u9700\u6c42\uff0c\u7279\u5225\u662f\u5728 ESR1 \u8207 PIK3CA \u7a81\u8b8a\u540c\u6642\u51fa\u73fe\u7684\u60c5\u6cc1\u4e0b\u3002\u00a0 \u9019\u4e9b\u4ee4\u4eba\u9f13\u821e\u7684\u521d\u6b65\u6578\u64da\u986f\u793a\uff0c\u8a72\u806f\u5408\u7642\u6cd5\u5177\u6709\u5ef6\u9577\u81e8\u5e8a\u6548\u76ca\u7684\u6f5b\u529b\uff0c\u800c\u5176\u5b89\u5168\u6027\u4ea6\u5c6c\u53ef\u63a7\uff0c\u7686\u56e0\u5b83\u53ef\u4ee5\u540c\u6642\u91dd\u5c0d ESR1 \u8207 PIK3CA \u7a81\u8b8a\uff0c\u5f9e\u800c\u6709\u53ef\u80fd\u907f\u514d\u5c0d\u6bcf\u500b\u9776\u9ede\u9010\u4e00\u63a1\u7528\u5e8f\u5217\u6cbb\u7642\u7684\u9700\u8981\u3002\u300d Menarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff1a\u300c\u57fa\u65bc\u6211\u5011\u53bb\u5e74\u5728\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u770b\u5230\u7684\u6578\u64da\uff0c\u6211\u5011\u7e7c\u7e8c\u5c0d\u57c3\u62c9\u53f8\u7fa4\u5728\u8207\u4e0d\u540c\u4f5c\u7528\u6a5f\u5236\u85e5\u7269\u7d44\u6210\u7684\u591a\u7a2e\u806f\u5408\u7642\u6cd5\u4e2d\uff0c\u91dd\u5c0d ER+\/HER2\u2212 \u8f49\u79fb\u6027\u4e73\u764c\u6240\u5c55\u73fe\u51fa\u7684\u6f5b\u5728\u81e8\u5e8a\u6548\u76ca\u611f\u5230\u9f13\u821e\u3002 \u6211\u5011\u7684\u7814\u7a76\u7bc4\u570d\u5ee3\u6cdb\uff0c\u6db5\u84cb\u65e9\u671f\u4e73\u764c\uff0c\u4ee5\u53ca\u591a\u7a2e\u91dd\u5c0d ER+\/HER2- \u8f49\u79fb\u6027\u4e73\u764c\u7684\u806f\u5408\u7642\u6cd5\uff08\u5305\u62ec\u8207\u5361\u5e15\u585e\u66ff\u5c3c\u7684\u806f\u5408\u7642\u6cd5\uff09\uff0c\u5c55\u73fe\u51fa\u6211\u5011\u81f4\u529b\u70ba\u764c\u75c7\u60a3\u8005\u5e36\u4f86\u5177\u6f5b\u5728\u8b8a\u9769\u6027\u6cbb\u7642\u65b9\u6848\u7684\u627f\u8afe\u3002\u300d \u6b64\u5916\uff0c\u5176\u4ed6\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u7684\u6578\u64da\u4ea6\u5c07\u65bc\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u5927\u6703\u4e0a\u516c\u4f48\u3002 \u4ee5\u4e0b\u662f\u5373\u5c07\u8209\u884c\u7c21\u5831\u7684\u5b8c\u6574\u540d\u55ae\uff1a \u7c21\u5831\u6a19\u984c\uff1a\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c\u6cbb\u7642 ER+\/HER2- \u665a\u671f\u4e73\u764c\u60a3\u8005\uff1aELEVATE \u7814\u7a76\uff08\u4e00\u9805\u7b2c 1b\/2 \u671f\u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\uff09\u7684\u6700\u65b0\u9032\u5c55\u6458\u8981\u7de8\u865f\uff1a1098\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 212 \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1a Wassim McHayleh \u7c21\u5831\u6a19\u984c\uff1aADELA\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u5206\u7d44\u7684\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\uff0c\u5c0d\u6bd4\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u5b89\u6170\u5291\u5728\u60a3\u6709 ER+\/HER2- \u665a\u671f\u4e73\u764c\u4e14\u816b\u7624\u5e36\u6709 ESR1 \u7a81\u8b8a\uff0c\u4e26\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642\u9023\u540c CDK4\/6 \u6291\u5236\u5291*# \u5f8c\u75c5\u60c5\u60e1\u5316\u60a3\u8005\u4e2d\u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1154\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 262b \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1a Antonio Llombart-Cussac \u7c21\u5831\u6a19\u984c\uff1aELECTRA\uff1a\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u591a\u4e2d\u5fc3\u3001\u7b2c 1b\/2 \u671f\u7814\u7a76\uff0c\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u5728\u60a3\u6709\u8166\u90e8\u8f49\u79fb\u7684 ER+\/HER2- \u4e73\u764c\u60a3\u8005\u4e2d\u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1155\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 263a \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aNuhad Ibrahim \u7c21\u5831\u6a19\u984c\uff1aCAPELA\uff1a\u4e00\u9805\u7b2c 2 \u671f\u591a\u4e2d\u5fc3\u958b\u653e\u6a19\u7c64\u96a8\u6a5f\u7814\u7a76\uff0c\u8a55\u4f30\u5361\u57f9\u4ed6\u6ff1 (capecitabine) \u806f\u5408\u57c3\u62c9\u53f8\u7fa4\uff0c\u76f8\u8f03\u65bc\u55ae\u7368\u4f7f\u7528\u5361\u57f9\u4ed6\u6ff1\u6cbb\u7642\u665a\u671f\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u4e73\u764c (TBCRC 070)* \u7684\u7642\u6548\u6458\u8981\u7de8\u865f\uff1aTPS1156\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 263b \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aKristina Fanucci \u7c21\u5831\u6a19\u984c\uff1aELEGANT\uff1a\u5728\u4e00\u9805\u5168\u7403\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\u4e2d\uff0c\u6bd4\u8f03\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u7528\u65bc\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548 \u6458\u8981\u7de8\u865f\uff1aTPS1153\u7c21\u5831\u65e5\u671f\u53ca\u6642\u9593\uff1a2026 \u5e74 6 \u6708 1 \u65e5\uff1b\u4e0b\u5348 1:30 \u2013 \u4e0b\u5348 4:30\uff08\u7f8e\u570b\u4e2d\u90e8\u6642\u9593\uff09\u5730\u9ede\uff1a\u7b2c 262a \u865f\u6d77\u5831\u677f\u5831\u544a\u4f5c\u8005\uff1aAditya Bardia *\u8868\u793a\u7814\u7a76\u8005\u767c\u8d77\u7814\u7a76\u6216\u5408\u4f5c\u7814\u7a76 #ADELA \u7814\u7a76\u662f\u4e00\u9805\u8207 MEDSIR \u5171\u540c\u8d0a\u52a9\u7684\u95dc\u9375\u6027\u7814\u7a76 \u95dc\u65bc\u57c3\u62c9\u53f8\u7fa4\u81e8\u5e8a\u958b\u767c\u8a08\u5283 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u5728\u591a\u9805\u7531\u516c\u53f8\u8d0a\u52a9\u7684\u8f49\u79fb\u6027\u4e73\u764c\u81e8\u5e8a\u7814\u7a76\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u53ef\u4f5c\u55ae\u85e5\u6cbb\u7642\u6216\u8207\u5176\u4ed6\u7642\u6cd5\u806f\u5408\u4f7f\u7528\u3002 ELEVATE (NCT05563220) \u662f\u4e00\u9805\u7b2c 1b\/2 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u5206\u5225\u8207\u963f\u57f9\u5229\u897f (alpelisib)\u3001\u4f9d\u7dad\u83ab\u53f8 (everolimus)\u3001\u5361\u5e15\u585e\u66ff\u5c3c (capivasertib)\u3001\u5e15\u535a\u897f\u5c3c (palbociclib)\u3001\u745e\u535a\u897f\u5229 (ribociclib) \u6216\u963f\u8c9d\u99ac\u897f\u5229 (abemaciclib) \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\u3002 ELECTRA (NCT05386108) \u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u7b2c 1b\/2 \u671f\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u963f\u8c9d\u99ac\u897f\u5229\u6cbb\u7642 ER+\u3001HER2- \u4e73\u764c\u60a3\u8005\u3002 \u8a72\u7814\u7a76\u7684\u7b2c 2 \u671f\u90e8\u5206\u6703\u8a55\u4f30\u6b64\u6cbb\u7642\u65b9\u6848\u5c0d\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6548\u7528\u3002 ELCIN (NCT05596409) \u662f\u4e00\u9805\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u7528\u65bc\u6cbb\u7642 ER+\u3001HER2- \u665a\u671f \/ \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\uff0c\u9019\u4e9b\u60a3\u8005\u5148\u524d\u66fe\u63a5\u53d7\u904e\u4e00\u81f3\u5169\u7a2e\u5167\u5206\u6ccc\u6cbb\u7642\uff0c\u4e26\u4e14\u5728\u8f49\u79fb\u6027\u968e\u6bb5\u672a\u66fe\u4f7f\u7528 CDK4\/6 \u6291\u5236\u5291\u3002 ADELA (NCT06382948) \u662f\u4e00\u9805\u7b2c 3 \u671f\u96a8\u6a5f\u3001\u96d9\u76f2\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u806f\u5408\u4f9d\u7dad\u83ab\u53f8\u7528\u65bc\u6cbb\u7642\u4f34\u6709 ESR1 \u57fa\u56e0\u7a81\u8b8a (ESR1-mut) \u816b\u7624\u7684 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002 ELEGANT (NCT06492616) \u662f\u4e00\u9805\u7b2c 3 \u671f\u81e8\u5e8a\u8a66\u9a57\uff0c\u65e8\u5728\u8a55\u4f30\u57c3\u62c9\u53f8\u7fa4\u8207\u6a19\u6e96\u5167\u5206\u6ccc\u7642\u6cd5\u76f8\u6bd4\uff0c\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u6dcb\u5df4\u7d50\u967d\u6027\u3001ER+\u3001HER2- \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c\u7537\u5973\u60a3\u8005\u7684\u7642\u6548\u3002 \u57c3\u62c9\u53f8\u7fa4\u4ea6\u6b63\u5728\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\u63a5\u53d7\u8a55\u4f30\uff0c\u6db5\u84cb\u8f49\u79fb\u6027\u4e73\u764c\u53ca\u65e9\u671f\u75be\u75c5\u9818\u57df\u3002 \u82e5\u8981\u532f\u5831\u7591\u4f3c\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u900f\u904e\u96fb\u90f5 adverseevents@menarinistemline.com \u806f\u7d61 Stemline Therapeutics, Inc.\u3002 \u6240\u6709\u76f8\u95dc\u8cc7\u8a0a\u5747\u8f09\u65bc https:\/\/stemline.com\/contact\/\u3002 \u57c3\u62c9\u53f8\u7fa4\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u8a0a\u53ef\u898b\u65bc https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu#product-info \u95dc\u65bc The Menarini Group The Menarini Group\uff08\u7f8e\u7d0d\u91cc\u5c3c\u96c6\u5718\uff09\u662f\u570b\u969b\u9802\u5c16\u7684\u88fd\u85e5\u53ca\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u70ba 55 \u5104\u7f8e\u5143\uff0c\u50f1\u7528\u903e 17,000 \u540d\u54e1\u5de5\u3002 Menarini \u5c08\u6ce8\u65bc\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u79d1\u3001\u816b\u7624\u79d1\u3001\u80f8\u8154\u79d1\u3001\u8178\u80c3\u79d1\u3001\u50b3\u67d3\u75c5\u79d1\u3001\u7cd6\u5c3f\u75c5\u79d1\u3001\u708e\u75c7\u53ca\u93ae\u75db\u7b49\u7bc4\u7587\u3002 Menarini \u8a2d\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u884c\u92b7\u5168\u7403 140 \u500b\u570b\u5bb6\u3002 \u5982\u6b32\u4e86\u89e3\u66f4\u591a\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 \u95dc\u65bc Stemline Therapeutics Inc.Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u70ba Menarini Group \u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8\uff0c\u662f\u4e00\u9593\u8655\u65bc\u5546\u696d\u968e\u6bb5\u7684\u751f\u7269\u88fd\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u70ba\u60a3\u8005\u63d0\u4f9b\u7a81\u7834\u6027\u7684\u816b\u7624\u6cbb\u7642\u65b9\u6848\u3002 Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u57c3\u62c9\u53f8\u7fa4\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u7642\u6cd5\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u60a3\u6709\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c 2 \u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001ESR1 \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\uff0c\u4e26\u4e14\u5728\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\u75c5\u60c5\u4ecd\u51fa\u73fe\u60e1\u5316\u7684\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\u60a3\u8005\u3002 Stemline \u4ea6\u5728\u7f8e\u570b\u3001\u6b50\u6d32\u53ca\u5176\u4ed6\u5168\u7403\u5730\u5340\u92b7\u552e\u4ed6\u683c\u7d22\u8299 (tagraxofusp-erzs)\u3002\u9019\u662f\u4e00\u7a2e\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u7d30\u80de\u816b\u7624 (BPDCN) \u60a3\u8005\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002 \u6b64\u5916\uff0cStemline \u5728\u6b50\u6d32\u92b7\u552e\u585e\u5229\u5c3c\u7d22 (selinexor)\uff0c\u9019\u662f\u4e00\u7a2e\u7528\u65bc\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1 (\u51fa\u53e3\u86cb\u767d 1) \u6291\u5236\u5291\u3002 \u8a72\u516c\u53f8\u4ea6\u5206\u5225\u91dd\u5c0d\u4e73\u764c\u53ca\u8840\u6db2\u60e1\u6027\u816b\u7624\u9069\u61c9\u75c7\uff0c\u9032\u884c\u591a\u9805\u6709\u95dc\u57c3\u62c9\u53f8\u7fa4\u548c\u4ed6\u683c\u7d22\u8299\u7684\u9069\u61c9\u75c7\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u4e14\u64c1\u6709\u9f90\u5927\u7684\u81e8\u5e8a\u7814\u767c\u7ba1\u7dda\uff0c\u7576\u4e2d\u5305\u62ec\u591a\u7a2e\u8655\u65bc\u4e0d\u540c\u958b\u767c\u968e\u6bb5\u3001\u91dd\u5c0d\u591a\u7a2e\u5be6\u9ad4\u816b\u7624\u548c\u8840\u6db2\u60e1\u6027\u816b\u7624\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\u3002 \u672c\u65b0\u805e\u7a3f\u4e2d\u6240\u63d0\u53ca\u7684\u7814\u7a76\u6027\u85e5\u7269\u806f\u5408\u7642\u6cd5\u53ca\u672a\u7d93\u6279\u51c6\u7684\u9069\u61c9\u75c7\uff0c\u5176\u5b89\u5168\u8207\u7642\u6548\u5c1a\u672a\u7372\u5f97\u7f8e\u570b\u98df\u54c1\u53ca\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\u3001\u6b50\u6d32\u85e5\u54c1\u7ba1\u7406\u5c40 (EMA) \u6216\u4efb\u4f55\u5176\u4ed6\u76e3\u7ba1\u6a5f\u69cb\u7684\u8b49\u5be6\u3002 \u00a0","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=440460#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=440460"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=440460#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/05\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/05\/Menarini_Industrie_Farmaceutiche_Riunite_Logo-1.jpg","width":400,"height":121},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=440460#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"Menarini Group \u65bc 2026 \u5e74\u7f8e\u570b\u81e8\u5e8a\u816b\u7624\u5b78\u6703 (ASCO) \u9031\u5e74\u5927\u6703\u4e0a\u767c\u8868\u7b2c 1b\/2 \u671f ELEVATE \u7814\u7a76\u4e2d\uff0c\u4f7f\u7528\u57c3\u62c9\u53f8\u7fa4 (Elacestrant) \u806f\u5408\u5361\u5e15\u585e\u66ff\u5c3c (Capivasertib) \u6cbb\u7642 ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u6700\u65b0\u6578\u64da\u3002"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/440460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=440460"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/440460\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/440461"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=440460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=440460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=440460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}